View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2014	Mar. 11, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Celsion CORP
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		19,984,703
Entity Public Float			$ 68,261,264
Amendment Flag	false
Entity Central Index Key	0000749647
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated Balance Sheets - USD ($)	Dec. 31, 2014	Dec. 31, 2013
In Process Research and Development [Member]
Other assets:
In-process research and development	$ 25,801,728
Cash and cash equivalents	12,686,881	$ 5,718,504
Investment securities – available for sale, at fair value	24,173,406	37,156,381
Accrued interest receivable on investment securities	210,030	212,048
Advances and deposits on clinical programs	200,821	111,635
Other current assets	235,133	563,551
	37,506,271	43,762,119
Property and equipment (at cost, less accumulated depreciation and amortization of $1,633,517 and $1,264,190, respectively)	1,170,497	832,886
Goodwill	1,976,101
Security deposit on letter of credit	150,000	200,000
Deferred financing fees	68,049	844,249
Other assets	21,886	31,318
	28,017,764	1,075,567
Total assets	66,694,532	45,670,572
Current liabilities:
Accounts payable ─ trade	3,480,225	1,452,436
Other accrued liabilities	2,456,365	2,707,653
Notes payable - current portion	3,654,231	10,891
Deferred revenue – current portion	500,000	500,000
Total current liabilities	10,090,821	4,670,980
Earn-Out milestone liability	13,663,710
Common stock warrant liability	275,008	3,026
Note payable – non-current portion	6,053,065	5,000,000
Deferred revenue – non-current portion	3,500,000	4,000,000
Other liabilities – noncurrent	286,592	472,731
Total liabilities	33,869,196	14,146,737
Commitments and contingencies	0	0
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at December 31, 2014 and 2013, respectively)	0	0
Common stock - $0.01 par value (75,000,000 shares authorized; 20,097,603 and 13,737,970 shares issued at December 31, 2014 and 2013 and 19,984,203 and 13,604,975 shares outstanding at December 31, 2014 and 2013, respectively)	200,976	137,380
Additional paid-in capital	229,778,703	203,139,142
Accumulated other comprehensive loss	(16,032)	(44,166)
Accumulated deficit	(195,073,702)	(169,287,157)
	34,889,945	33,945,199
Treasury stock, at cost (113,400 and 132,995 shares at December 31, 2014 and 2013, respectively)	(2,064,609)	(2,421,364)
Total stockholders’ equity	32,825,336	31,523,835
Total liabilities and stockholders’ equity	$ 66,694,532	$ 45,670,572

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Accumulated depreciation (in Dollars)	$ 1,633,517	$ 1,264,190
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	20,097,603	13,737,970
Common stock, shares outstanding	19,984,203	13,604,975
Treasury stock, shares	113,400	132,995

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Licensing revenue	$ 500,000	$ 500,000
Operating expenses:
Research and development	14,969,382	9,364,228	$ 15,770,166
General and administrative	8,860,549	6,547,257	6,372,551
Acquisition costs	1,385,263
Total operating expenses	25,215,194	15,911,485	22,142,717
Loss from operations	(24,715,194)	(15,411,485)	(22,142,717)
Other income (expense):
Gain (loss) from valuation of common stock warrant liability	204,279	8,090,636	(4,117,534)
Gain from valuation of earn-out milestone liability	213,949
Investment income (loss), net	77,194	(12,744)	52,322
Interest expense	(1,326,438)	(915,235)	(359,413)
Other income (expense)	51,937	(2,530)	(1,040)
Total other (expense) income	(779,079)	7,160,127	(4,425,665)
Net loss	(25,494,273)	(8,251,358)	(26,568,382)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		(4,601,410)
Net loss attributable to common shareholders	$ (25,494,273)	$ (12,852,768)	$ (26,568,382)
Net loss per common share – basic and diluted (in Dollars per share)	$ (1.38)	$ (0.95)	$ (3.44)
Weighted average common shares outstanding – basic and diluted (in Shares)	18,472,399	13,540,566	7,730,904

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss	$ (25,494,273)	$ (8,251,358)	$ (26,568,382)
Changes in:
Realized loss on investment securities recognized in investment income, net	24,727	92,364	7,580
Unrealized (loss) gain on investment securities	3,407	(9,923)	142,513
Other comprehensive income	28,134	82,441	150,093
Comprehensive loss	$ (25,466,139)	$ (8,168,917)	$ (26,418,289)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	$ (25,494,273)	$ (8,251,358)	$ (26,568,382)
Non-cash items included in net loss:
Depreciation and amortization	369,327	339,229	281,489
Change in fair value of common stock warrant liability	(204,279)	(8,090,636)	4,117,534
Change in fair value of earn-out milestone liability	(213,949)
Cash received for non-refundable research and development fee		5,000,000
Deferred revenue	(500,000)	(500,000)
Stock based compensation	2,585,132	1,235,437	1,143,764
Shares issued out of treasury	64,483	98,046	107,049
Amortization of deferred finance charges and debt discount associated with note payable	437,994	336,387	43,215
Amortization of patent license fee	7,500	7,500	7,500
Change in deferred rent liability	(24,375)	(18,940)	55,256
Loss realized on sale of investment securities	24,727	92,364	7,580
Net changes in:
Interest receivable on investments	2,018	(146,123)	177,820
Prepaid expenses and other current assets	77,468	(121,235)	585,595
Deposits and other assets	1,932	(116,181)	18,721
Accounts payable	1,764,563	(887,332)	(1,344,379)
Other accrued liabilities	(251,288)	1,497,566	(776,955)
Net cash used in operating activities	(21,353,020)	(9,525,276)	(22,144,193)
Cash flows from investing activities:
Purchases of investment securities	(29,825,918)	(66,323,059)	(16,394,358)
Proceeds from sale and maturity of investment securities	42,812,300	37,194,375	18,478,591
Cash used in acquisition of EGEN, Inc., net of cash received	(2,820,649)
Refund on security for letter of credit	50,000	50,000
Purchases of property and equipment	(672,256)	(57,494)	(613,390)
Net cash provided by (used in) by investing activities	9,543,477	(29,136,178)	1,470,843
Cash flows from financing activities:
Proceeds from sale of preferred stock, net of issuance costs		13,616,432
Proceeds from sale of common stock equity, net of issuance costs	13,788,811	15,622,955
Proceeds from exercise of common stock warrants	0	261,944	10,106,557
Proceeds from exercise of common stock options	0	184,047	697,220
Proceeds from note payable	5,000,000	4,763,803	4,825,494
Principal payments on note payable	(10,891)	(5,060,711)	(110,287)
Net cash provided by financing activities	18,777,920	29,388,470	15,518,984
Increase (decrease) in cash and cash equivalents	6,968,377	(9,272,984)	(5,154,366)
Cash and cash equivalents at beginning of period	5,718,504	14,991,488	20,145,854
Cash and cash equivalents at end of period	12,686,881	5,718,504	14,991,488
Cash paid for:
Interest	$ 892,600	$ 637,183	$ 359,413

Consolidated Statements of Change in Stockholders' Equity - USD ($)	Preferred Stock [Member] Preferred Stock [Member]	Preferred Stock [Member] Common Stock [Member]	Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Redeemable Convertible Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Redeemable Convertible Preferred Stock [Member]	Hercules Warrant [Member] Additional Paid-in Capital [Member]	Hercules Warrant [Member]	Common Stock Warrants (Member) Common Stock [Member]	Common Stock Warrants (Member) Additional Paid-in Capital [Member]	Common Stock Warrants (Member)	Direct and ATM [Member] Common Stock [Member]	Direct and ATM [Member] Additional Paid-in Capital [Member]	Direct and ATM [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Total
Balance at December 31 at Dec. 31, 2011															$ 75,332	$ 158,887,403	$ (2,884,125)	$ (267,700)	$ (129,608,341)	$ 26,193,568
Balance at December 31 (in Shares) at Dec. 31, 2011															7,374,739		158,384
Net loss																			(26,568,382)	(26,568,382)
Unrealized gain on investments available for sale																		150,093		$ 150,093
Valuation of common stock warrants in connection with notes payable				$ 73,654	$ 73,654
Conversion of convertible securities								$ 8,455	$ 10,156,437	$ 10,164,892
Conversion of convertible securities (in Shares)								845,526												847,715
Stock-based compensation expense																1,143,764				$ 1,143,764
Issuance of restricted stock and option exercise															$ 586	696,643				697,220
Issuance of restricted stock and option exercise (in Shares)															58,618
Issuance of common stock out of treasury																	$ 193,614		(86,565)	107,049
Issuance of common stock out of treasury (in Shares)															10,624		(10,624)
Balance at December 31 at Dec. 31, 2012															$ 84,373	170,957,891	$ (2,690,511)	(126,607)	(156,263,288)	$ 11,961,858
Balance at December 31 (in Shares) at Dec. 31, 2012															8,289,507		147,760			729,825
Net loss																			(8,251,358)	$ (8,251,358)
Stock issued, new issues											$ 25,880	$ 15,598,670	$ 15,624,550	$ 150		18,217,702				18,217,852
Stock issued, new issues (in Shares)											2,588,032			15,001
Classification of warrants to/from common stock warrant liability, net																(3,809,730)				(3,809,730)
Non-cash dividend on beneficial conversion feature associated with the preferred stock offering																			(4,601,410)	(4,601,410)
Unrealized gain on investments available for sale																		82,441		$ 82,441
Valuation of common stock warrants in connection with notes payable				$ 521,763	$ 521,763
Conversion of convertible securities	$ (150)	$ 26,828	$ (26,678)					$ 180	$ 261,764	$ 261,944
Conversion of convertible securities (in Shares)	(15,001)	2,682,759						18,021												15,833
Stock-based compensation expense																1,235,437				$ 1,235,437
Issuance of restricted stock and option exercise															$ 129	183,918				184,047
Issuance of restricted stock and option exercise (in Shares)															12,872
Issuance of common stock out of treasury																	$ 269,147		(171,101)	98,046
Issuance of common stock out of treasury (in Shares)															14,765		(14,765)
Fractional share payment															$ (10)	(1,595)				(1,605)
Fractional share payment (in Shares)															(981)
Balance at December 31 at Dec. 31, 2013															$ 137,380	203,139,142	$ (2,421,364)	(44,166)	(169,287,157)	$ 31,523,835
Balance at December 31 (in Shares) at Dec. 31, 2013															13,604,975		132,995			863,462
Net loss																			(25,494,273)	$ (25,494,273)
Stock issued, new issues											$ 36,036	$ 13,752,775	$ 13,788,811
Stock issued, new issues (in Shares)											3,603,604
Common stock issued in connection with the acquisition of EGEN, Inc. assets															$ 27,122	10,823,855				10,850,977
Common stock issued in connection with the acquisition of EGEN, Inc. assets (in Shares)															2,712,188
Unrealized gain on investments available for sale																		28,134		28,134
Valuation of common stock warrants in connection with notes payable						$ (521,763)	$ (521,763)
Stock-based compensation expense																2,513,042				2,513,042
Issuance of restricted stock and option exercise															$ 438	71,652				72,090
Issuance of restricted stock and option exercise (in Shares)															43,841
Issuance of common stock out of treasury																	$ 356,755		(292,272)	64,483
Issuance of common stock out of treasury (in Shares)															19,595		(19,595)
Balance at December 31 at Dec. 31, 2014															$ 200,976	$ 229,778,703	$ (2,064,609)	$ (16,032)	$ (195,073,702)	$ 32,825,336
Balance at December 31 (in Shares) at Dec. 31, 2014															19,984,203		113,400			1,751,773

Note 1 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Celsion Corporation, a Delaware corporation based in Lawrenceville, New Jersey, and its wholly owned subsidiary, CLSN Laboratories, Inc., also a Delaware corporation, referred to herein as “Celsion”, “we”, or “the Company,” as the context requires, is a fully-integrated oncology drug development company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Our lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Our pipeline also includes GEN-1 (formerly known as EGEN-001), a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. We have three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. We are working to develop and commercialize more efficient, effective and targeted oncology therapies based on our technologies, with the goal to develop novel therapeutics that maximize efficacy while minimizing side-effects common to cancer treatments.

Basis of Presentation

The accompanying consolidated financial statements of Celsion have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States and include the accounts of the Company and CLSN Laboratories, Inc. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from these estimates.

Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business. See Note 18 for a summary of subsequent events.

Certain items in the prior period financial statements have been reclassified to conform to the current period presentation.

Revenue Recognition

At the inception of each collaborative agreement that includes milestone payments, the Company evaluates whether each milestone is substantive on the basis of the contingent nature of the milestone, specifically reviewing factors such as the scientific and other risks that must be overcome to achieve the milestone, as well as the level of effort and investment required. Milestones that are not considered substantive and that do not meet the separation criteria are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Payments received or reasonably assured after performance obligations are met completely are recognized as earned.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance.

Fair Value of Financial Instruments

The carrying values of financial instruments approximate their respective fair values.

Short Term Investments

The Company classifies its investments in marketable securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments - Debt and Equity Securities. Available-for-sale securities consist of debt and equity securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders’ equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company’s short term investments consist of corporate bonds and government agency bonds.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately $369,000, $339,000 and $281,500 for years ended December 31, 2014, 2013 and 2012, respectively.

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model.

Deposits

Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature.

Goodwill and In-Process Research and Development

During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 5, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date.

Patent Licenses

The Company has purchased several licenses for rights to patented technologies. Patent license costs of $63,125 have been capitalized and are amortized on a straight-line basis over the estimated life of the related patent. As of December 31, 2014, the total accumulated amortization expense is $41,500. The weighted-average amortization period for these assets is 10 years.

Comprehensive Income (Loss)

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income and its components in the Company’s consolidated financial statements. The objective of ASC 220 is to report a measure (comprehensive income (loss)) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners.

Research and Development

Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.

Net Loss Per Common Share

Basic and diluted net income/(loss) per common share was computed by dividing net income/(loss) for the year by the weighted average number of shares of Common Stock outstanding, both basic and diluted, during each period. The impact of Common Stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.

For the years ended December 31, 2014, 2013 and 2012, outstanding equity awards of 1,751,773, 863,462 and 729,825 shares, respectively, and warrants outstanding to purchase 5,069,815, 3,170,520 and 1,747,478 shares, respectively, were considered anti-dilutive and therefore were not included in the calculation of diluted shares.

Income Taxes

Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category. The Company remains subject to examination for income tax returns for the years ending after 2010.

Stock-Based Compensation

Compensation costs for all stock-based awards is measured at fair value on the date of the grant and recognized over the service period for awards expected to vest. Such value is recognized as expense over the service period. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the current estimates, such amounts will be recorded as cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by FASB and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Topic 606). This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. It will be effective for our first quarter of 2017 and early adoption is not permitted.

Note 2 - Financial Condition

12 Months Ended

Dec. 31, 2014

Financial Condition [Abstract]

Financial Condition [Text Block]

2. FINANCIAL CONDITION

Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s product candidates, and applications and submissions to the Food and Drug Administration. The Company believes these expenditures are essential for the commercialization of its technologies. As a result of these expenditures, as well as general and administrative expenses, the Company has an accumulated deficit of $195 million as of December 31, 2014.

The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company’s ability to achieve profitability is dependent upon its ability to obtain governmental approvals, produce, and market and sell its new product candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The operating results of the Company have fluctuated significantly in the past. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company’s control.

The Company will need substantial additional funding in order to complete the development, testing and commercialization of its oncology product candidates and we have made a significant commitment to heat-activated liposome research and development projects and it is our intention at least to maintain, and possibly increase, the pace and scope of these activities. The commitment to these new projects will require additional external funding, at least until the Company is able to generate sufficient cash flow from sale of one or more of its products to support its continued operations.

If adequate funding is not available, the Company may be required to delay, scale back or terminate certain aspects of its operations or attempt to obtain funds through unfavorable arrangements with partners or others that may force it to relinquish rights to certain of its technologies, products or potential markets or that could impose onerous financial or other terms. Furthermore, if the Company cannot fund its ongoing development and other operating requirements, particularly those associated with its obligations to conduct clinical trials under its licensing agreements, it will be in breach of these licensing agreements and could therefore lose its license rights, which could have material adverse effects on its business. Management is continuing its efforts to obtain additional funds so that the Company can meet its obligations and sustain operations.

Note 3 - Short-term Investments Available for Sale

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

3. SHORT TERM INVESTMENTS AVAILABLE FOR SALE

Short term investments available for sale of $24,173,406 and $37,156,381 as of December 31, 2014 and 2013, respectively, consist of money market funds, commercial paper, corporate debt securities, and government agency debt securities. They are valued at estimated fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in Accumulated Other Comprehensive Income.

Securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.

A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows:

	December 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Certificate of deposit	$	5,000,000	$	4,996,568	$	3,840,000	$	3,835,083
Bonds- corporate issuances		19,189,438		19,176,838		33,360,576		33,321,298
Total short-term investments	$	24,189,438	$	24,173,406	$	37,200,576	$	37,156,381

	December 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value

Short-term investment maturities
Within 3 months	$	16,881,490	$	16,872,158	$	7,799,032	$	7,797,689
Between 3-12 months		7,307,948		7,301,248		29,401,544		29,358,692
Total	$	24,189,438	$	24,173,406	$	37,200,576	$	37,156,381

Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows:

	2014			2013			2012

Interest and dividends accrued and paid	$	1,015,182		$	748,947		$	712,947
Accretion of investment premium		(913,261	)		(669,344	)		(652,960	)
Losses on investment maturity and sales, net		(24,727	)		(92,346	)		(7,580	)
	$	77,194		$	(12,744	)	$	52,322

In 2009, the Company recorded an equity investment of approximately $108,000 for stock received as settlement of a transition agreement the Company previously entered into. The $108,000 asset value reflected the estimated net realizable value of 903,112 shares of Medifocus Inc. at the time of settlement. As of December 31, 2011, this entire amount had been reduced to $0 and was charged as an unrealized loss in other comprehensive loss. During the fourth quarter of 2012, the Company sold this stock for approximately $138,000, thereby recording a realized gain of approximately $30,000 in investment income and reversing the cumulative unrealized loss of $108,000 in other comprehensive loss.

The following table shows the Company’s investment securities gross unrealized losses and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at December 31, 2014 and 2013. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.

	December 31, 2014					December 31, 2013
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	–		–			$	6,650,095	$	1,907
Short-term investments with unrealized losses		24,173,406		(16,032	)		30,506,286		(46,073	)
Total	$	24,173,406	$	(16,032	)	$	37,156,381	$	(44,166	)

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Note 4 - Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

4. FAIR VALUES OF FINANCIAL INSTRUMENTS

FASB Accounting Standards Codification (ASC) Section 820, Fair Value Measurements and Disclosures, establishes a three tier level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability.

The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 inputs) or matrix pricing, which is a mathematical technique widely used in the industry to value debt securities without relying exclusively on quoted prices for the specific securities but rather by relying on the securities’ relationship to other benchmark quoted securities (Level 2 inputs).

Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature. There were no transfers of assets of liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during 2014 except for the change in the fair market value of the warrant liability and the change in the earn-out milestone liability were included in earnings.

Assets and liabilities measured at fair value are summarized below:

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets /Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of December 31, 2014
Short-term investments available for sale	$	24,173,406	$	24,173,406		─	─

Non-recurring items as of December 31, 2014
In-process research and development (Note 5)	$	25,801,728	─		─		$	25,801,728

Goodwill (Note 5)	$	1,976,101	─		─		$	1,976,101

Recurring items as of December 31, 2013
Short-term investments available for sale	$	37,156,381	$	37,156,381	─		─

Liabilities:
Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)	$	275,008	─		─		$	275,008

Earn-out milestone liability (Note 12)	$	13,663,710	─		─		$	13,663,710

As of December 31, 2013
Common stock warrant liability (Note 13)	$	3,026	─		─		$	3,026

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 5 - Acquisition of EGEN, Inc.

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

5. ACQUISITION OF EGEN, INC.

On June 20, 2014, Celsion completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama Corporation (EGEN) pursuant to an Asset Purchase Agreement (EGEN Purchase Agreement). CLSN Laboratories, Inc., a Delaware corporation and a wholly-owned subsidiary of Celsion (CLSN Laboratories), acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.

The total aggregate purchase price for the acquisition is up to $44.4 million, which includes potential future payments of up to $30.4 million contingent upon achievement of certain milestones set forth in the EGEN Purchase Agreement (Earn-Out Payments). At the closing, Celsion paid approximately $3.0 million in cash after expense adjustment and issued 2,712,188 shares of its common stock to EGEN. The shares of Celsion’s common stock were issued in a private transaction exempt from registration under the Securities Act of 1933, as amended (the Securities Act), pursuant to Section 4(2) thereof. In addition, 670,070 shares of Celsion common stock are issuable to EGEN on or after August 2, 2016 pending satisfactory resolution of any post-closing adjustments of expenses and EGEN’s indemnification obligations under the EGEN Purchase Agreement (Holdback Shares). A Registration Statement (File No. 333-198786) was filed on September 16, 2014 and declared effective on September 30, 2014 for the resale of the shares of common stock issued and issuable to EGEN under the EGEN Purchase Agreement.

The Earn-Out Payments of up to $30.4 million will become payable, in cash, shares of Celsion common stock or a combination thereof, at Celsion’s option, as follows:

●

Certain specified development milestones relating to GEN-1 to treat ovarian cancer patients ($12.0 million);

●

Certain specified development milestones relating to GEN-1 to treat GBM cancer patients ($12.0 million); and

●

A self-liquidating payment of 50% of all fees received from the licensing of TherSilence (up to $6.0 million).

On June 9, 2014, Celsion borrowed an additional $5 million pursuant to a certain Loan and Security Agreement dated as of November 25, 2013, by and between Celsion and Hercules Technology Growth Capital, Inc. (see Note 10). Celsion used the loan proceeds to pay the upfront cash payment at closing and certain transaction costs incurred by Celsion in connection with the acquisition.

The EGEN Purchase Agreement contains customary representations and warranties regarding EGEN and Celsion, covenants regarding the conduct of EGEN’s business prior to the consummation of the acquisition, indemnification provisions, termination and other provisions customary for transactions of this nature.

The acquisition of EGEN was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. The fair value of the consideration transferred for the acquisition is approximately $27.6 million determined as follows:

Consideration Paid at Closing
Cash, net of cash acquired	$	2,821,000
Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)		9,438,000

Future Consideration
Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)		1,441,000
Earn-Out Payments (at fair value*)		13,878,000

Total fair value of consideration	$	27,578,000

* The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2014, the Company fair valued these milestones at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of these milestones from June 30, 2014.

Under the acquisition method of accounting, the total purchase price is allocated to EGEN’s net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. The table below summarizes the preliminary estimated fair values of EGEN’s net tangible and intangible assets and liabilities on the acquisition date. The purchase price allocations are preliminary and subject to change as more detailed analyses are completed and additional information with respect to the fair values of the assets and liabilities acquired becomes available.

Property and equipment, net		35,000
In-process research and development		25,802,000
Goodwill		1,976,000
Total assets:		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

The preliminary purchase price exceeds the estimated fair value of the net assets acquired by approximately $2.0 million which was recorded as goodwill. Transaction costs associated with the acquisition of assets from EGEN are included in Acquisition Costs in the Condensed Consolidated Statement of Operations and totaled $1,385,263 from the date of acquisition on June 20, 2014 through December 31, 2014.

Acquired In-Process Research and Development (IPR&D)

Acquired IPR&D consists of EGEN's drug technology platforms: TheraPlas^™ and TheraSilence^™. The fair value of the IPR&D drug technology platforms was estimated to be $25.8 million as of the acquisition date using the Multi-Period Excess Earnings Method (MPEEM) which is a form of the income approach. Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset’s incremental after-tax cash flows (excess earnings) remaining after deducting the market rates of return on the estimated value of contributory assets (contributory charge) over its remaining useful life.

To calculate fair value of the IPR&D programs under the MPEEM, we used projected cash flows discounted at a rate considered appropriate given the significant inherent risks associated with drug development by development-stage companies. Cash flows were calculated based on estimated projections of revenues and expenses related to the IPR&D programs and then reduced by a contributory charge on requisite assets employed. Contributory assets included debt-free working capital, net fixed assets and assembled workforce. Rates of return on the contributory assets were based on rates used for comparable market participants. Cash flows were assumed to extend through a seven-year market exclusivity period. The resultant cash flows were then discounted to present value using a weighted-average cost of equity capital for companies with profiles substantially similar to that of Celsion, which we believe represents the rate that market participants would use to value the assets. The projected cash flows were based on significant assumptions, including the indication in which we will pursue development of IPR&D programs, the time and resources needed to complete the development and regulatory approval of IPR&D programs, estimates of revenue and operating profit related to the program considering its stage of development, the life of the potential commercialized product, market penetration and competition, and risks associated with achieving commercialization, including delay or failure to obtain regulatory approvals to conduct clinical studies, failure of clinical studies, delay or failure to obtain required market clearances, and intellectual property litigation.

As of the closing of the acquisition, the IPR&D is considered indefinite lived intangible assets and will not be amortized. IPR&D will be reviewed for possible impairment on an annual basis by each year end or more frequently if events are indicative of impairment.

Pro Forma Information

The following unaudited pro forma information presents our condensed results of operations as if the acquisition of EGEN had occurred on January 1, 2013:

	Year ended December 31,
	2014			2013
Revenues	$	500,000		$	627,628
Loss from operations		(24,898,725	)		(18,247,339	)
Net loss applicable to common shareholders		(25,662,572	)		(15,952,832	)

The above unaudited pro forma condensed consolidated financial information is presented for illustrative purposes only. It is not necessarily indicative of what the results of operations actually would have been had the acquisition been completed on the date indicated. In addition, it does not purport to project the future operating results of the combined entity.

The operations of EGEN are included with our operations from the period of closing of the acquisition on June 20, 2014 to the end of 2014. The Company’s Statement of Operations included $2,297,000 of operating expenses related to the operations of the acquired business for the period from the date of acquisition (June 20, 2014) through December 31, 2014.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Note 6 - Property, Plant and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

6. PROPERTY AND EQUIPMENT:

	December 31, 2014			December 31, 2013
Machinery and equipment (5-7 year life)	$	2,298,516		$	1,674,206
Furniture and fixtures (3-5 year life)		235,679			153,051
Leasehold improvements (5-7 year life)		269,819			269,819
		2,804,014			2,097,076
Less accumulated depreciation and amortization		(1,633,517	)		(1,264,190	)
Total	$	1,170,497		$	832,886

Note 7 - Other Accrued Liabilities

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

7. OTHER ACCRUED LIABILITIES

Other accrued liabilities at December 31, 2014 and 2013 include the following:

	December 31, 2014		December 31, 2013
Amounts due to Contract Research Organizations and other contractual agreements	$	857,730	$	1,711,934
Accrued payroll and related benefits		961,440		900,434
Accrued professional fees		502,300		63,500
Accrued interest on notes payable		96,875	–
Other		38,020		31,785
Total	$	2,456,365	$	2,707,653

Note 8 - Notes Payable

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

8. NOTES PAYABLE

Hercules Credit Agreement

In November 2013, the Company entered into a loan agreement with Hercules Technology Growth Capital, Inc. (Hercules) which permits up to $20 million in capital to be distributed in multiple tranches (the Hercules Credit Agreement). The Company drew the first tranche of $5 million upon closing of the Hercules Credit Agreement in November 2013 and used approximately $4 million of the proceeds to repay the outstanding obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation as discussed further below. On June 10, 2014, the Company closed the second $5 million tranche under the Hercules Credit Agreement. The proceeds were used to fund the $3.0 million upfront cash payment associated with Celsion's acquisition of EGEN, as well as the Company’s transaction costs associated with the EGEN acquisition. Upon the closing of this second tranche, the Company has drawn down a total of $10 million under the Hercules Credit Agreement.

The obligations under the Hercules Credit Agreement are in the form of secured indebtedness bearing interest at a calculated prime-based variable rate (11.25% per annum since inception). Payments under the loan agreement are interest only for the first twelve months after loan closing, followed by a 30-month amortization period of principal and interest through the scheduled maturity date.

In connection with the Hercules Credit Agreement, the Company incurred cash expenses of $122,378 which were recorded as deferred financing fees. These deferred financing fees are being amortized as interest expense using the effective interest method over the life of the loan. Also in connection with the Hercules Credit Facility, the Company paid loan origination fees of $230,000 which has been classified as debt discount. This amount is being amortized as interest expense using the effective interest method over the life of the loan.

As a fee in connection with the Hercules Credit Agreement, the Company issued Hercules a warrant for a total of 97,493 shares of the Company’s common stock (the Hercules Warrant) at a per share exercise price of $3.59, exercisable for cash or by net exercise from November 25, 2013. Upon the closing of the second tranche on June 10, 2014, this warrant became exercisable for an additional 97,493 shares of the Company’s common stock. The Hercules Warrant will expire November 25, 2018. Hercules has certain rights to register the common stock underlying the Hercules Warrant pursuant to a Registration Rights Agreement with the Company dated November 25, 2013. The registration rights expire on the date when such stock may be sold under Rule 144 without restriction or upon the first year anniversary of the registration statement for such stock, whichever is earlier. The common stock issuable pursuant to the Hercules Warrant was filed pursuant to Rule 415 under the Securities Act of 1933 on the Prospectus for Registration Statement No. 333-193936 and was declared effective on September 30, 2014.

The Company valued the Hercules Warrant issued at the inception of the loan using the Black-Scholes option pricing model and recorded $521,763 in 2013 as deferred financing fees. In calculating the value of the warrants, the Company assumed a volatility rate of 102%, risk free interest rate of 1.37%, an expected life of 5 years, a stock price of $3.55 (closing price on date of the Hercules Warrant) and no expected forfeitures nor dividends. In the second quarter of 2014, the Company reassessed the classification of the warrants and concluded the original amount should be reclassified from deferred financing fees and equity. Therefore, other assets and additional paid in capital were both reduced by the $521,763. The Company then valued the warrant for the initial 97,493 shares of the Company’s common stock as of the inception of the loan and recorded $260,928 as a debt discount to be amortized as interest expense using the effective interest method over the life of the loan and recognized a warrant liability for this amount. In connection with the closing of the second $5 million tranche on June 9, 2014, the Company then valued the warrant for the additional 97,493 shares of the Company’s common stock which became available and exercisable as of the date and recorded $215,333 as a debt discount to be amortized as interest expense using the effective interest method over the life of the loan and recognized a warrant liability for this amount. In calculating the value of the warrant for the additional shares of the Company’s common stock on June 10, 2014, the Company assumed a volatility rate of 104%, risk free interest rate of 1.69%, an expected remaining life of 4.5 years, a stock price of $3.07 (closing price June 9, 2014) and no expected forfeitures nor dividends. The warrant liability will be fair valued at the end of each quarter and the resulting change in fair value will be recognized in net income.

Also in connection with each of the $5.0 million tranches, the Company will be required to pay an end of term charge equal to 3.5% of each original loan amount at time of maturity. Therefore, these amounts totaling $350,000 are being amortized as interest expense using the effective interest method over the life of the loan.

For the year ended December 31, 2014, the Company incurred $892,188 in interest expense and amortized $433,839 as interest expense for deferred fees, debt discount and end of term charges in connection with the Hercules Credit Agreement.

The Hercules Credit Agreement contains customary covenants, including covenants that limit or restrict the Company’s ability to grant liens, incur indebtedness, make certain restricted payments, merge or consolidate and make dispositions of assets. Upon the occurrence of an event of default under the Hercules Credit Agreement, the lenders may cease making loans, terminate the Hercules Credit Agreement, declare all amounts outstanding to be immediately due and payable and foreclose on or liquidate the Company’s assets that comprise the lenders’ collateral. The Hercules Credit Agreement specifies a number of events of default (some of which are subject to applicable grace or cure periods), including, among other things, non-payment defaults, covenant defaults, a material adverse effect on the Company or its assets, cross-defaults to other material indebtedness, bankruptcy and insolvency defaults and material judgment defaults. The Company has maintained compliance with these covenants.

Following is a schedule of future principle payments before debt discount due on the Hercules Credit Agreement:

	For the year ending December 31,

2015	$	3,654,231
2016		4,091,595
2017		2,254,174
2018 and thereafter	–
Total	$	10,000,000

Oxford & Horizon Credit Agreement

In June 2012, the Company entered into a Loan and Security Agreement (the Oxford & Horizon Credit Agreement) with Oxford Finance LLC (Oxford) and Horizon Technology Finance Corporation (Horizon). The Oxford & Horizon Credit Agreement provided for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon. The aggregate loan amount could have been advanced in two tranches of $5 million each. The first tranche (the Term A Loan) was made available to the Company on June 27, 2012 and the second tranche was to be made available, if at all, during the period beginning on the date that the Company achieved positive data in its Phase III clinical trial of RFA and ThermoDox® (the HEAT Study) and ending on March 31, 2013. On January 31, 2013, the Company announced it did not meet the primary endpoint of the HEAT Study.

The Term A Loan was originally scheduled to mature on October 15, 2015. As a result of the Hercules Credit Agreement discussed above, the Company terminated the Oxford & Horizon Credit Agreement and repaid the outstanding principle, accrued interest and termination fees totaling approximately $4.1 million.

The proceeds of the Oxford & Horizon Credit Agreement were used to fund the Company’s working capital and general corporate purposes. The obligations under the Oxford & Horizon Credit Agreement were secured by substantially all assets of the Company other than its intellectual property and certain other agreed-upon exclusions.

As a fee in connection with the Oxford & Horizon Credit Agreement, the Company issued warrants to Horizon and Oxford (the Oxford & Horizon Warrants) to purchase the number of shares of the Company’s common stock equal to 3% of each loan amount divided by the exercise price of $13.14 per share, which was calculated as the average NASDAQ closing price of the Company’s common stock for the three days prior to the funding of the loan amount. This resulted in 11,415 warrant shares issued in connection with the Term A Loan. The Oxford & Horizon Warrants issued in connection with the Term A Loan are exercisable for cash or by net exercise and will expire seven years after their issuance, which is June 27, 2019. The Company valued the Oxford & Horizon Warrants using the Black-Scholes option pricing model and recorded $73,654 as deferred financing fees. In calculating the value of the warrants, the Company assumed a volatility rate of 74.3%, risk free interest rate of 1.10%, an expected life of 3.5 years, a stock price of $12.60 which was the closing price on date of issuing the Oxford & Horizon Warrant) and no expected forfeitures nor dividends. In connection with the Oxford & Horizon Credit Agreement, the Company incurred cash expenses of $217,715 which were recorded as deferred financing fees in 2012. These deferred financing fees were amortized as interest expense over the life of the loan. During the first three months of 2013, the Company paid $146,874 in interest expense and amortized $31,560 of deferred financing fees as interest expense. The Term A Loan bore interest at a fixed rate of 11.75%.

Capital Lease

In November 2011, the Company financed $144,448 of lab equipment through a capital lease. This lease obligation had thirty monthly payments of $5,651 through February 2014. During 2014, the Company made principal and interest payments totaling $11,303 to satisfy the remaining obligation under this capital lease.

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

9. INCOME TAXES

A reconciliation of the Company’s statutory tax rate to the effective rate for the years ended December 31, 2014, 2013 and 2012 is as follows:

	2014			2013			2012

Federal statutory rate		34.0	%		34.0	%		34.0	%
State taxes, net of federal tax benefit		5.5			5.9			5.9
Recapture of alternative minimum tax	–			–			–
Valuation allowance		(39.5	)		(39.9	)		(39.9	)

Effective tax rate		–	%		–	%		–	%

The components of the Company’s deferred tax asset as of December 31, 2014 and 2013 are as follows:

	December 31,
In thousands	2014			2013

Net operating loss carry forwards	$	61,536		$	53,423
Compensation expense related to employee stock options		4,235			3,310
Subtotal		65,771			56,733
Valuation allowance		(65,771	)		(56,733	)
Total deferred tax asset	$	-		$	-

The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company’s ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. At this time, the Company has established a valuation reserve for all of its deferred tax assets. Such tax assets are available to be recognized and benefit future periods.

Following is a schedule of net operating loss carry forwards and their year of expiration:

Approximate Amount of Unused Operating Loss Carry Forwards (in $000s)		Expiration During Year Ended
$	5,003		2022
	2,292		2023
	15,655		2024
	8,174		2025
	7,367		2026
	10,716		2028
	14,300		2029
	18,045		2030
	21,386		2031
	20,558		2032
	10,319		2033
	21,896		2034
$	155,711

During 2014, 2013 and 2012 the Company performed analyses to determine if there were changes in ownership, as defined by Section 382 of the Internal Revenue Code that would limit its ability to utilize certain net operating loss and tax credit carry forwards. The Company determined that it experienced an ownership change, as defined by Section 382, in connection with certain common stock offerings on July 25, 2011, February 5, 2013 and on June 3, 2013. As a result, the utilization of the Company's federal tax net operating loss carry forwards generated prior to the ownership changes are limited. As of December 31, 2013, the Company has net operating loss carry forwards for U.S. federal and state tax purposes of approximately $156 million, before excluding net operating losses that have been limited as a result of Section 382 limitations. The annual limitation due to Section 382 for net operating loss carry forward utilization is approximately $4.9 million per year for approximately $90 million in net operating loss carry forwards existing at the ownership change occurring on July 25, 2011, approximately $1.4 million per year for approximately $34 million of additional net operating losses occurring from July 2011 to the ownership change that occurred on February 5, 2013 and approximately $1.5 million per year for approximately $34 million of additional net operating losses occurring from February 5, 2013 to the ownership change that occurred on June 3, 2013. The utilization of these net operating loss carry forwards may be further limited if the Company experiences future ownership changes as defined in Section 382 of the Internal Revenue Code.

Note 10 - Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

10. STOCKHOLDERS’ EQUITY

In August 2012, the Company filed with the Securities and Exchange Commission a $75 million shelf registration statement on Form S-3 that allowed the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock or preferred stock. This shelf registration was declared effective on September 14, 2012.

During 2013, we received approximately $0.4 million of gross proceeds from the exercise of warrants and stock options to purchase approximately 30,893 shares of the Company’s common stock. During 2012, we received approximately $10.8 million of gross proceeds from the exercise of warrants and stock options to purchase approximately 904,144 shares of the Company’s common stock. We did not have any warrant nor option exercises in 2014.

January 2014 Common Stock Offering

On January 15, 2014, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 3,603,604 shares of its common stock, par value $0.01 per share, and warrants to purchase up to 1,801,802 shares of Common Stock, for an aggregate purchase price of approximately $15 million (the January 2014 Common Stock Offering). The shares of common stock and warrants were sold in units, with each unit consisting of one share of common stock, a Series A warrant to purchase 0.25 share of common stock and a Series B warrant to purchase 0.25 share of common stock. Each unit was sold at a purchase price of $4.1625. Each Series A warrant will be exercisable at any time on or after its issuance date and until the five-year anniversary of the issuance date. Each Series B warrant will be exercisable at any time on or after its issuance date and until the one-year anniversary of the issuance date. Each warrant has an exercise price of $4.10 per share. Under the purchase agreement, the Company was prohibited, for a period of nine months after the closing, from effecting or entering into an agreement to issue common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, common stock to the extent such issuance or sale involves certain variable conversion, exercise or exchange prices or such agreement provides for sale of securities at a price to be determined in the future.

Shares issued in acquisition of EGEN, Inc.

As more fully discussed in Note 5, the Company issued 2,712,188 shares of its common stock to the shareholders of EGEN, Inc. to acquire certain assets of EGEN. The shares of Celsion’s common stock were issued in a private transaction exempt from registration under the Securities Act of 1933, as amended (the Securities Act), pursuant to Section 4(2) thereof. In addition, 670,070 shares of Celsion common stock are issuable to EGEN shareholders on or after August 2, 2016 pending satisfactory resolution of any post-closing adjustments of expenses and EGEN’s indemnification obligations under the EGEN Purchase Agreement (Holdback Shares). The common stock issued and issuable to EGEN pursuant to the Asset Purchase Agreement were filed pursuant to Rule 415 under the Securities Act of 1933 on the Prospectus for Registration Statement No. 333-198786 and was declared effective on September 30, 2014.

Controlled Equity Offering

On February 1, 2013, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which Celsion may offer and sell, from time to time, through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (the “ATM Shares”) pursuant to the Company’s previously filed and effective Registration Statement on Form S-3. Under the ATM Agreement, Cantor may sell ATM Shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the our common stock or to or through a market maker. From February 1, 2013 through February 25, 2013, the Company sold and issued an aggregate of 1,195,927 shares of common stock under the ATM Agreement, receiving approximately $6.8 million in net proceeds.

The Company is not obligated to sell any ATM Shares under the ATM Agreement. Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. In addition, pursuant to the terms and conditions of the ATM Agreement and subject to the instructions of the Company, Cantor may sell ATM Shares by any other method permitted by law, including in privately negotiated transactions.

The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregate offering price of $25 million and (ii) the termination of the ATM Agreement by Cantor or the Company. The ATM Agreement may be terminated by Cantor or the Company at any time upon 10 days' notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material adverse change in the Company. The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of ATM Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company also reimbursed Cantor for legal fees and disbursements of $50,000 in connection with entering into the ATM Agreement. In connection with the February 2013 Preferred Stock Offering discussed below, the Company agreed to not sell any ATM Shares for a period of one year from February 26, 2013. In connection with the Common Stock Offering below, the Company agreed to not sell any ATM Shares until June 3, 2014. In connection with the January 2014 securities offering discussed in Note 15 below, the Company agreed to not sell any ATM Shares until July 22, 2014. The Company currently has approximately $18 million remaining under the ATM Agreement.

February 2013 Preferred Stock Offering

On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 15,000.00422 shares of its Series A 0% convertible preferred stock and the warrants to purchase shares of its common stock, for an aggregate purchase price of approximately $15.0 million (the February 2013 Preferred Stock Offering). The closing of the February 2013 Preferred Stock Offering occurred on February 26, 2013, in which the Company received approximately $15.0 million in gross proceeds. Subject to certain ownership limitations, shares of Series A 0% convertible preferred stock are convertible, at the option of the holder thereof, into an aggregate of up to 2,682,764 shares of common stock, and the warrants are exercisable to purchase an aggregate of up to 1,341,382 shares of common stock. Each warrant has an exercise price of $5.31 per share, equal to the closing bid price of common stock on February 21, 2013. The warrants are immediately exercisable and expire five years after the date of issuance.

Upon issuance, we estimated the fair value of the warrants issued in the February 2013 Preferred Stock Offering to be approximately $5.4 million using the Black-Scholes pricing model. Also, upon issuance, we recognized approximately $4.6 million as a one-time, non-cash deemed dividend related to the beneficial conversion feature connected to the preferred stock in the Preferred Stock Offering.

Assumptions used in the valuation of the warrants issued in the February 2013 Preferred Stock Offering were as follows:

Risk-free interest rate	0.78	%
Expected volatility	102.23	%
Expected life (in years)	5.0
Expected forfeiture rate	0.0	%
Expected dividend yield	0.0	%

As of September 30, 2013, all 2,682,764 shares of common stock in the aggregate were issued upon conversion of all 15,000.00422 shares of the Series A 0% convertible preferred stock.

May 2013 Common Stock Offering

On May 30, 2013, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 1,392,109 shares of its common stock for an aggregate purchase price of approximately $9.8 million (the “Common Stock Offering”). The closing of the Common Stock Offering occurred on June 3, 2013. The issuance of common stock in the Common Stock Offering was made pursuant to the Company’s previously filed and effective Registration Statement on Form S-3 (File No. 333-183286), the base prospectus dated September 14, 2012 filed as part of such Registration Statement, and the prospectus supplement filed with the Securities and Exchange Commission on June 3, 2013. The Securities Purchase Agreement also contained representations, warranties, indemnification and other provisions customary for transactions of this nature.

Prior to the closing of the Common Stock Offering, there were an insufficient number of authorized shares to complete the transaction. The investors in the Common Stock Offering also held warrants to purchase common stock of the Company which were issued in connection with previous offerings. Concurrent with the closing of the Common Stock Offering, the institutional investors agreed to waive their rights to exercise these warrants to purchase 1,398,816 shares of common stock of the Company (the “Waived Warrants”) until the Company has obtained stockholders’ approval to increase the number of its authorized shares of common stock in conjunction with the proposed reverse stock split of its outstanding shares of common stock. At the Company’s 2013 Annual Meeting of Stockholders held on July 19, 2013, the Company’s stockholders voted to approve the proposal to grant discretionary authority to the Board of Directors to amend the Certificate of Incorporation of the Company, as amended, to effect, at any time on or prior to the date of the 2014 Annual Meeting of Stockholders, a reverse stock split at an exchange ratio within the specified range and to set the number of authorized shares effective immediately after the reverse stock split at 75 million shares. On October 28, 2013, the Company announced that it affected a 1-for-4.5 reverse stock split of its common stock. See Reverse Stock Split below for further information.

Prior to the closing of the Common Stock Offering, the warrants described above were originally recorded as equity at the fair value on the date of issuance. In accordance with ASC 815-40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the Waived Warrants were required to be liability classified immediately after the closing of the Common Stock Offering on June 3, 2013 because there were an insufficient number of common shares authorized to permit the full exercise of the warrants. Therefore on June 3, 2013, the Company reclassified the fair value of the Waived Warrants totaling approximately $9.1 million from equity to a liability. The Waived Warrants were required to be recorded at fair value at each balance sheet date with changes in fair value recorded in earnings until such time as there were a sufficient number of common shares authorized to permit the full exercise of the warrants (see Note 11). In connection with the Reverse Stock Split as more fully described below, these warrants were valued as of October 28, 2013, and the Company reclassified the fair value of the Waived Warrants totaling approximately $5.3 million from a liability to equity.

Following is a summary list of the Waived Warrants:

Shares of common stock associated with the Waived Warrants		Expiration Date of Waived Warrants	Strike Price		Per Share Fair Value on June 3, 2013		Per Share Fair Value on October 28, 2013

	1,323,496	2/26/2018	$	5.31	$	6.60	$	3.86
	31,243	7/25/2016	$	18.99	$	4.41	$	2.10
	12,628	7/6/2016	$	14.09	$	4.81	$	2.40
	31,448	11/25/2017	$	12.47	$	5.56	$	3.16

Assumptions used in the valuation of the Waived Warrants associated with the June 3, 2013 Common Stock Offering were as follows:

	June 3, 2013				October 28, 2013

Risk-free interest rate	0.50	-	1.03	%	0.59	-	1.31	%
Expected volatility	102.9	-	110.9	%	105.1	-	111.8	%
Expected life (in years)	3.1	-	4.7	%	2.7	-	4.3	%
Expected forfeiture rate		0.0		%		0.0		%
Expected dividend yield		0.00		%		0.00		%

Reverse Stock Split

On October 28, 2013, the Company affected a 1-for-4.5 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on October 29, 2013. As of that date, each 9 shares of issued and outstanding common stock and equivalents were consolidated into 2 shares of common stock. In addition, at the market open on October 29, 2013, the Company’s common stock started trading under a new CUSIP number 15117N404 although the Company’s ticker symbol, CLSN, remained unchanged.

The reverse stock split was previously approved by the Company’s stockholders at the 2013 Annual Meeting held on July 19, 2013, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:

●

To increase the market price of the Company’s common stock making it more attractive to a broader range of institutional and other investors,

●

To provide the Company with additional capital resources and flexibility sufficient to execute its business plans including the establishment of strategic relationships with other companies and to ensure its ability to raise additional capital as necessary, and

●

As previously announced, to facilitate expanding the Company’s business or product lines through potential acquisitions.

Immediately prior to the reverse stock split, the Company had 61,226,873 shares of common stock outstanding which consolidated into 13,604,975 shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. Holders of fractional shares have been paid out in cash for the fractional portion with the Company’s overall exposure for such payouts consisting of a nominal amount. The number of outstanding options and warrants were adjusted accordingly, with outstanding options being reduced from approximately 3.9 million to approximately 0.9 million and outstanding warrants being reduced from approximately 13.8 million to approximately 3.1 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 11 - Stock Based Compensation

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

11. STOCK BASED COMPENSATION

Employee Stock Options

The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options may not be less than the fair market value of Celsion’s Common Stock on the date the options are granted. Options generally vest over various time frames or upon milestone accomplishments. Some vest immediately. Others vest over a period between one and five years. The options generally expire ten years from the date of the grant.

2001 Stock Option Plan

In 2001, the Board of Directors adopted a stock plan for directors, officers and employees (the “2001 Plan”) under which 148,148 shares were reserved for future issuance. The purpose of the 2001 Plan was to promote long-term growth and profitability of Celsion by providing key people with incentives to improve stockholder value and contribute to the growth and financial success of Celsion, and to enable the company to attract, retain and reward the best available persons for positions of substantial responsibility.

2004 Stock Incentive Plan

In 2004, the Board of Directors adopted a stock plan for directors, officers and employees (the “2004 Plan”) under which 148,148 shares were reserved for future issuance. The plan provides for stock instruments to be issued enabling the holder thereof to acquire Common stock of the Company at prices determined by the Company’s Board of Directors. The purpose of the 2004 Plan was to promote the long-term growth and financial success of the Company and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The 2004 Plan permitted the granting of awards in the form of incentive stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. The 2004 Plan terminated in 2014, 10 years from the date of the Plan’s adoption by the Company’s stockholders.

Any options forfeited or terminated under the 2001 Plan and 2004 Plan are rolled into the 2007 Stock Incentive Plan for future issuance.

2007 Stock Incentive Plan

In 2007, the Company adopted the Celsion Corporation 2007 Stock Incentive Plan (the 2007 Plan) under which 222,222 shares were authorized for issuance. The purpose of the 2007 Plan is to promote the long-term growth and profitability of the Company by providing incentives to improve stockholder value and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The 2007 Plan permits the granting of equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. At the Annual Meetings of Stockholders of Celsion held on June 25, 2010, June 7, 2012 and June 20, 2014, the stockholders approved amendments to the Plan. The only material difference between the original Plan and the amended Plan was the number of shares of common stock available for issuance under the amended Plan which was increased by 222,222 to a total of 444,444 shares in 2010, by 500,000 to a total of 944,444 shares in 2012 and by 2,500,000 to a total of 3,444,444 shares in 2014.

The Company has issued stock awards to employees, directors and vendors out of the stock option plans. Options and are generally granted at market value on the date of the grant.

Incentive stock options may be granted to purchase shares of Common Stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive option granted to an eligible employee owning more than 10% of the outstanding stock must be at least 110% of the such fair market value on the date of grant. Only officers and key employees may receive incentive stock options; all other qualified participants may receive non-qualified stock options.

Option awards vest upon terms determined by the Board of Directors. Restricted stock awards, performance stock awards and stock options are subject to accelerated vesting in the event of a change of control. The Company issues new shares to satisfy its obligations from the exercise of options.

During the year ended December 31, 2014, 2013 and 2012, 1,040,950, 187,888 and 148,553 equity awards, respectively, were granted under the 2007 Plan. During 2014, 2013 and 2012, a total of 131,850, 41,379 and 66,019 equity awards, respectively, were canceled or expired under the plans collectively. During 2014, 2013 and 2012, 21,341, 12,873 and 56,710 shares of the Company’s common stock were issued collectively as a result of either options being exercised or restricted stock awards vesting.

In 2007 an option to purchase 95,555 shares of the Company's common stock was issued to the Company's Chief Executive Officer. This option vested in equal installments over four years and was separately registered with the Securities and Exchange Commission (the "SEC") and was not issued under any of the Employee Stock Incentive Plans.

Collectively, for all the stock option plans as of December 31, 2014, there were a total of 3,674,270 shares reserved, which were comprised of 1,751,773 equity awards granted and 1,922,497 equity awards available for future issuance.

Total compensation cost charged related to employee stock options and non-vested restricted stock awards amounted to $2.6 million, $1.2 million and $1.1 million for the years ended December 31, 2014, 2013 and 2012, respectively. No compensation cost related to share-based payments arrangements was capitalized as part of the cost of any asset at these same periods. As of December 31, 2014, there was $1.3 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.6 years. The weighted average grant-date fair values of the equity awards granted during the years ended December 31, 2014, 2013 and 2012 were $3.18, $3.40 and $7.28, respectively.

Equity Awards Issued to Consultants for Services

The Company periodically issues equity awards to consultants in exchange for services provided. The fair value of options granted is measured in accordance with ASC 718, Compensation – Stock Compensation, using the Black-Scholes option pricing model and recorded as an expense in the period in which such services are received. Generally, the terms of these plans require that the exercise price of such awards may not be less than the fair market value of the Company’s Common Stock on the date the equity awards are granted. Consultant equity awards generally vest over various time frames or upon milestone accomplishments. Some vest immediately upon issuance. The equity awards generally expire within 10 years from the date of grant. There were 5,555 and 5,387 awards issued to consultants during the years ended December 31, 2013 and 2012, respectively. No awards were granted to consultants during the year ended December 31, 2014.

A summary of stock option awards as of December 31, 2014 and changes during the three years ended December 31, 2014, is presented below:

Stock Options	Number Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2012		691,809		$	16.88
Granted		145,611			10.08
Exercised		(47,575	)		14.67
Canceled or expired		(64,316	)		29.43
Outstanding at December 31, 2012		725,529		$	14.63
Granted		187,777			4.39
Exercised		(12,429	)		14.67
Canceled or expired		(38,972	)		16.79
Outstanding at December 31, 2013		861,905		$	12.29
Granted		1,014,700			3.53
Exercised	–			–
Canceled or expired		(131,850	)		19.05
Outstanding at December 31, 2014		1,744,755			7.20		7.5	$	-

Exercisable at December 31, 2014		990,936		$	9.71		6.1	$	-

A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2014 and changes during the three years ended December 31, 2014, is presented below:

Restricted Stock	Number Outstanding			Weighted Average Exercise Price
Non-vested stock awards outstanding at January 1, 2012		12,193		$	14.22
Granted		2,942			16.47
Vested and issued		(9,135	)		15.17
Forfeited		(1,703	)		12.56
Non-vested stock awards outstanding at December 31, 2012		4,297		$	14.63
Granted		111			5.36
Vested and issued		(444	)		8.40
Forfeited		(1,855	)		15.69
Non-vested stock awards outstanding at December 31, 2013		2,109		$	14.13
Granted		26,250			3.46
Vested and issued		(21,341	)		4.77
Forfeited	–			–
Non-vested stock awards outstanding at December 31, 2014		7,018		$	3.32

A summary of stock options outstanding at December 31, 2014 by price range is as follows:

			Options Outstanding						Options Exercisable
		Range of Exercise Prices	Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price

$ 2.00	-	$3.99		956,700		9.4	$	3.53		293,266		9.4	$	3.54	$
$ 4.00	-	$8.99		185,778		7.6	$	4.46		131,044		7.2	$	4.41
$ 9.00	-	$13.49		434,445		4.9	$	11.12		401,461		4.7	$	11.25
$ 13.50	-	$31.49		165,870		3.4	$	20.81		163,203		3.3	$	20.80
Above $31.50				1,962		0.5	$	38.07		1,962		0.5	$	38.09
				1,744,755						990,936

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s nonqualified stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	Year Ended December 31,
	2014				2013				2012
Risk-free interest rate	2.31	to	2.75	%	0.85	to	1.19	%	1.09	to	2.97	%
Expected volatility	94.3	-	100.7	%	83.4	-	97.9	%	80.8	-	82.3	%
Expected life (in years)		10			5.25	to	6.00		5.00	to	6.25
Expected forfeiture rate		10		%	5.0	to	7.5	%		7.5		%
Expected dividend yield		0.0		%		0.0		%		0.0		%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury strips as published in the Wall Street Journal in effect at the time of grant. The model incorporates exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data. The expected life of the fiscal 2014, 2013 and 2012 grants was generated using the simplified method as allowed under Securities and Exchange Commission Staff Accounting Bulletin No. 107.

Note 12 - Earn Out Milestone Liability

12 Months Ended

Dec. 31, 2014

Earn Out Milestone Liability Disclosure [Abstract]

Earn Out Milestone Liability Disclosure [Text Block]

12. EARN-OUT MILESTONE LIABILIITY

The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 7.0 years). The earn-out milestone liability will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statements. As of December 31, 2014, the Company fair valued the earn-out milestone liability at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of earn-out milestone liability from June 30, 2014. The fair value of the earn-out milestone liability at December 31, 2014 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.2 to 6.5 years).

The following is a summary of the changes in the earn-out milestone liability for 2014:

Balance at January 1, 2014	–
Fair value of Earn-Out Payments at date of EGEN Purchase Agreement (Note 5)		13,878,204
Gain from the adjustment for the change in fair value included in net income		(213,494	)
Balance at December 31, 2014	$	13,663,710

Note 13 - Warrants

12 Months Ended

Dec. 31, 2014

Warrants [Abstract]

Warrants [Text Block]

13. WARRANTS

As more fully described in Note 10, the Company completed a series of equity financing transactions in 2014 and 2013 that included the issuance of warrants to purchase 1,801,802 and 1,341,382 shares, respectively, of the Company’s common stock. In connection with the Hercules Credit Agreement and the Horizon & Oxford Credit Agreement the Company entered into in November 2013 and June 2012 as more fully described in Note 8, the Company issued warrants to purchase 194,986 and 11,415 shares, respectively, of the Company’s common stock. During 2013 and 2012, the Company received gross proceeds of approximately $0.3 million and $10.1 million, respectively, from the exercise of warrants to purchase 15,833 and 847,715 shares of common stock, respectively. No warrants were exercised during 2014.

Following is a summary of all warrant activity for the three years ended December 31, 2014:

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at January 1, 2012		2,583,778		$	14,18
Warrants issued in connection with the Oxford & Horizon Credit Agreement as more fully described in Note 8		11,415			13.14
Warrants exercised for common stock in 2012		(847,715	)		12.11
Warrants outstanding at December 31, 2012		1,747,478		$	15.17

Warrants issued in connection with 2013 equity transactions		1,341,382			5.31
Warrants issued in connection with the Hercules Credit Agreement (November 2013 tranche) as more fully described in Note 8		97,493			3.59
Warrants exercised for common stock in 2013		(15,833	)		14.63
Warrants outstanding at December 31, 2013		3,170,520		$	10.65

Warrants issued in connection with the January 2014 equity transaction		1,801,802			4.10
Warrants issued in connection with the Hercules Credit Agreement (June 2014 tranche) as more fully described in Note 8		97,493			3.59
Warrants outstanding at December 31, 2014		5,069,815		$	8.18


Aggregate intrinsic value of outstanding warrants at December 31, 2014	–

Weighted average remaining contractual terms (years)		2.4

Common Stock Warrant Liability

In September 2009, the Company closed a registered direct offering with a select group of institutional investors that raised gross proceeds of $7.1 million and net proceeds of $6.3 million. In connection with this registered direct offering, the Company issued 484,478 shares of its common stock and warrants to purchase 224,239 shares of common stock. The warrants have an exercise price of $23.58 per share and are exercisable at any time on or after the six month anniversary of the date of issuance and on or prior to 66 months after the date of issuance. Under the terms of the warrants, upon certain transactions, including a merger, tender offer or sale of all or substantially all of the assets of the Company, each warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option valuation model. Accordingly, pursuant to ASC 815.40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the warrants are recorded as a liability and then marked to market each period through the Statement of Operations in other income or expense. At the end of each subsequent quarter, the Company will revalue the fair value of the warrants and the change in fair value will be recorded as a change to the warrant liability and the difference will be recorded through the Statement of Operations in other income or expense.

As more fully described in Note 10, concurrent with the closing of the Common Stock Offering, the investors in this offering agreed to waive their rights to exercise the Waived Warrants to purchase 1,398,816 shares of common stock of the Company until the Company has obtained stockholders’ approval of increasing the number of its authorized shares of common stock in conjunction with the proposed reverse stock split of its outstanding shares of common stock. In accordance with ASC 815-40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the Waived Warrants were required to be classified as liabilities immediately after the closing of the Common Stock Offering on June 3, 2013 because there were an insufficient number of common shares authorized to permit the full exercise of the Waived Warrants if they were exercised. Therefore, the Company had reclassified the fair value of the Waived Warrants totaling approximately $9.1 million from equity to a liability as of June 3, 2013. The Waived Warrants were required to be recorded at fair value at each balance sheet date with changes in fair value recorded in earnings until such time as there are a sufficient number of common shares authorized to permit the full exercise of the warrants. In connection with the Reverse Stock Split, these warrants were valued as of October 28, 2013 and the Company reclassified the fair value of the Waived Warrants totaling approximately $5.3 million from a liability to equity.

As of December 31, 2014 and 2013, the Company recorded a common stock warrant liability of $275,008 and $3,026 million respectively. The fair value of the warrants associated with the September 2009 registered direct offering and the warrants associated with the Hercules loan as more fully described in Note 8 at December 31, 2014, 2013 and 2012 was calculated using the Black-Scholes option-pricing model with the following assumptions:

	December 31,
	2014			2013			2012
Risk-free interest rate		0.04 - 1.66	%		0.13	%		0.73	%
Expected volatility		40.9- 98.35	%		64.74	%		92.02	%
Expected life (in years)		0.25 -3.9			1.25			1.13
Expected forfeiture rate		0.0	%		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%		0.00	%

See Note 10 for the assumptions used at June 3, 2013 and October 28, 2013 for the Black-Scholes option-pricing model calculation for the Waived Warrants associated with the Common Stock Offering on the dates they were waived and when there became a sufficient number of common shares authorized to permit their full exercise.

As a result of this change in the warrant liability in 2014, the Company recorded a non-cash benefit of $204,279 in 2014. As a result of this change in the warrant liability in 2013, which included the change in the warrant liability associated with the Waived Warrants as discussed above, the Company recorded a non-cash benefit of $8.1 million during 2013. The change in the warrant liability during 2012 resulted in a non-cash loss of $4.1 million in 2012. The following is a summary of the changes in the common stock warrant liability for 2014, 2013 and 2012:

Balance at January 1, 2012	$	166,398
Benefit from the adjustment for the change in fair value included in net loss for 2011		4,117,534	)
Balance at December 31, 2012		4,283,932
Fair value of warrants classified as liability (see Note 10)		9,110,302
Fair value of warrants classified as equity (see Note 10)		(5,300,572	)
Gain from the adjustment for the change in fair value included in net loss		(8,090,636	)
Ending balance, December 31, 2013	$	3,026
Fair value of warrants classified as liability (see Note 8)		476,261
Gain from the adjustment for the change in fair value included in net income		(204,279	)
	$	275,008

Note 14 - Celsion Employee Benefit Plans

12 Months Ended

Dec. 31, 2014

Disclosure Text Block Supplement [Abstract]

Compensation and Employee Benefit Plans [Text Block]

14. CELSION EMPLOYEE BENEFIT PLANS

Celsion maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees over the age of 21. Participating employees may defer a portion of their pretax earnings, up to the IRS annual contribution limit. Commencing in the fourth quarter for 2008, the Company began making a matching contribution up to a maximum of 3% of an employee’s annual salary and the Company’s total contribution for the years ended December 31, 2014, 2013 and 2012 was $56,875, $57,239 and $60,360 respectively. The Company’s contribution was made in the form of our common stock.

Note 15 - Licenses of Intellectual Property and Patents

12 Months Ended

Dec. 31, 2014

Disclosure Text Block [Abstract]

Intangible Assets Disclosure [Text Block]

15. LICENSES OF INTELLECTUAL PROPERTY AND PATENTS

On November 10, 1999, the Company entered into a license agreement with Duke University under which the Company received worldwide exclusive rights (subject to certain exceptions) to commercialize and use Duke’s thermally sensitive liposome technology. The license agreement contains annual royalty and minimum payment provisions due on net sales. The agreement also required milestone-based royalty payments measured by various events, including product development stages, FDA applications and approvals, foreign marketing approvals and achievement of significant sales. However, in lieu of such milestone-based cash payments, Duke agreed to accept shares of the Company’s Common Stock to be issued in installments at the time each milestone payment is due, with each installment of shares to be calculated at the average closing price of the Common Stock during the 20 trading days prior to issuance.

The total number of shares issuable to Duke under these provisions is subject to adjustment in certain cases, and Duke has piggyback registration rights for public offerings taking place more than one year after the effective date of the license agreement. On January 31, 2003, the Company issued 253,691 shares of Common Stock to Duke University valued at $2.2 million as payment for milestone based royalties under this license agreement. An amendment to the Duke license agreement contains certain development and regulatory milestones, and other performance requirements that the Company has met with respect to the use of the licensed technologies. The Company will be obligated to make royalty payments based on sales to Duke upon commercialization, until the last of the Duke patents expire.

For the years ended December 31, 2014, 2013 and 2012, the Company has not incurred any expense under this agreement and will not incur any future liabilities until commercial sales commence.

Under the November 1999 license agreement with Duke, the Company has rights to the thermally sensitive liposome technology, including Duke’s US patents covering the technology as well as all foreign counter parts and related pending applications. Foreign counterpart applications have been issued in Europe, Hong Kong, Australia and Canada and have been allowed in Japan. The Japanese allowed application is expected to issue without hindrance in March of 2011. The European patent has been validated in Austria, Belgium, France, Germany, Great Britain, Italy, Luxembourg, Monaco, Spain and Switzerland. In addition, the Duke license agreement provides the Company with rights to multiple issued and pending US patents related to the formulation, method of making and use of heat sensitive liposomes. The Company’s rights under the license agreement with Duke University extend for the life of the last-to-expire of the licensed patents.

The Company has licensed from Valentis, CA certain global rights covering the use of pegylation for temperature sensitive liposomes.

In addition to the rights available to the Company under completed or pending license agreements, the Company is actively pursuing patent protection for technologies developed by the Company. Among these patents is a family of pending US and international patent applications which seek to protect the Company’s proprietary method of storing ThermoDox® which is critical for worldwide distribution channels.

ThermoDox® is a registered trademark in the United States, Argentina, Australia, Canada, China, Columbia, the European Communities: (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK), Hong Kong, Israel, Japan, New Zealand, Peru, Philippines, Russia, Singapore, South Korea and Taiwan. The Company has registered transliterations of ThermoDox® in China, Hong Kong, Japan, Singapore, South Korea and Taiwan. The Company has an additional 14 trademark protection applications pending for ThermoDox® in countries world-wide.

Finally, through proprietary information agreements with employees, consultants and others, the Company seeks to protect its own proprietary know-how and trade secrets. The Company cannot offer assurances that these confidentiality agreements will not be breached, that the Company will have adequate remedies for any breach, or that these agreements, even if fully enforced, will be adequate to prevent third-party use of the Company’s proprietary technology. Similarly, the Company cannot guarantee that technology rights licensed to it by others will not be successfully challenged or circumvented by third parties, or that the rights granted will provide the Company with adequate protection.

Note 16 - Technology Development and Licensing Agreements

12 Months Ended

Dec. 31, 2014

Licensing Transaction [Abstract]

Licensing Transaction [Text Block]

16. TECHNOLOGY DEVELOPMENT AND LICENSING AGREEMENTS

On May 7, 2012 the Company entered into a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox® in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (CHINA FDA). As of December 31, 2014, the Company has incurred approximately $209,000 in costs to be reimbursed to Hisun.

On January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to support our development of ThermoDox^® in mainland China, Hong Kong and Macau (the China territory). Following our announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate and are evaluating the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development of ThermoDox^® for the Greater China market. The $5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and will continue to be amortized over the 10 year term of the agreement, until such time as the parties find a mutually acceptable path forward on the development of ThermoDox^® based on findings of the ongoing post-study analysis of the HEAT Study data.

On July 19, 2013, the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox® as well as the technology transfer relating to the commercial manufacture of ThermoDox® for the China territory. This expanded collaboration includes development of the next generation liposomal formulation with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics.

Among the key provisions of the Celsion-Hisun Memorandum of Understanding are:

●

Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory;

●

Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and

●

Hisun will be granted a right of first offer for a commercial license to ThermoDox® for the sale and distribution of ThermoDox® in the China territory.

Note 17 - Contingent Liabilities and Commitments

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

17. CONTINGENT LIABILITIES AND COMMITMENTS

In July 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (Brandywine), a Delaware limited partnership for a 10,870 square foot premises located in Lawrenceville, New Jersey. In October 2011, the Company relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The lease has a term of 66 months and provides for 6 months rent free, with the first monthly rent payment of approximately $23,000 due and paid in April 2012. Also, as required by the Lease, the Company provided Brandywine with an irrevocable and unconditional standby letter of credit for $250,000, which the Company secured with an escrow deposit at its banking institution of this same amount. The standby letter of credit will be reduced by $50,000 on each of the 19th, 31st and 43rd months from the initial term, with the remaining $100,000 amount remaining until the Lease Term has expired. In connection with two $50,000 reductions of the standby letter of credit in April 2013 and 2014, the Company reduced the escrow deposit by $50,000 each time.

In connection with the EGEN Asset Purchase agreement in June 2014, the Company assumed the existing lease with another landlord for an 11,500 square foot premises located in Huntsville Alabama. This lease has a remaining term of 43 months with rent payments of approximately $23,200 per month.

The Company paid $425,443, $280,808 and $184,790 in connection with these leases in 2014, 2013 and 2012, respectively.

Following is a summary of the future minimum payments required under leases that have initial or remaining lease terms of one year or more as of December 31, 2014:

For the year ending December 31:	Operating Leases
2015	$	570,078
2016		575,513
2017		378,042
2018		23,200
2019 and beyond		—
Total minimum lease payments	$	1,546,833

Note 18 - Subsequent Events

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

18. SUBSEQUENT EVENTS

On January 20, 2015 the Company announced it had signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.

RCW breast cancer is difficult to treat and has a poor prognosis with a significant impact on a patient's quality of life. Patients with highly resistant tumors found on the chest wall often see their cancer progress despite previous treatment attempts including chemotherapy, radiation therapy and hormone therapy. There are approximately 25,000 to 35,000 incidence of RCW breast cancer in the EU alone and thermal therapy is a well-accepted strategy for treating patients. Recent findings from two Phase I studies and an ongoing open label Phase II study indicate that when combined with thermal therapy, ThermoDox^® can demonstrate significant overall response rates and tumor control in post mastectomy, refractory patients.

Early Access Programs (EAP) allow biopharmaceutical companies to provide eligible patients with ethical access to investigational medicines for unmet medical needs within the scope of the existing early access legislation. Access is provided in response to physician requests in a fully compliant manner, where no alternative treatment options are available to these patients. Celsion will provide ThermoDox^® to centers of excellence in the EU and Switzerland through its Early Access Program with myTomorrows, at prices that are comparable to chemotherapeutics used to treat this and other aggressive form of cancer. The Company expects to have ThermoDox® available for the EAP in the second quarter of 2015.

Note 19 - Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

19. SELECTED QUARTERLY FINANCIAL DATA (Unaudited)

(in thousands, except per share data)	Quarters Ended
	March 31			June 30			September 30			December 31
2014
Total revenue	$	125		$	125		$	125		$	125
Net loss		(5,423	)		(6,673	)		(6,942	)		(6,455	)
Basic and diluted net loss per share		(0.33	)		(0.38	)		(0.35	)		(0.32	)

2013
Total revenue	$	125		$	125		$	125		$	125
Net loss		(651	)		421			(4,072	)		(3,949	)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		(4,601	)	─			─			─
Basic and diluted net loss available to common shareholders per share		(0.48	)		0.03			(0.30	)		(0.29	)

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements of Celsion have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States and include the accounts of the Company and CLSN Laboratories, Inc. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from these estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business. See Note 18 for a summary of subsequent events. Certain items in the prior period financial statements have been reclassified to conform to the current period presentation.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition At the inception of each collaborative agreement that includes milestone payments, the Company evaluates whether each milestone is substantive on the basis of the contingent nature of the milestone, specifically reviewing factors such as the scientific and other risks that must be overcome to achieve the milestone, as well as the level of effort and investment required. Milestones that are not considered substantive and that do not meet the separation criteria are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Payments received or reasonably assured after performance obligations are met completely are recognized as earned.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds are not covered by FDIC insurance.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values.
Investment, Policy [Policy Text Block]	Short Term Investments The Company classifies its investments in marketable securities with readily determinable fair values as investments available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments - Debt and Equity Securities. Available-for-sale securities consist of debt and equity securities not classified as trading securities or as securities to be held to maturity. The Company has classified all of its investments as available-for-sale. Unrealized holding gains and losses on available-for-sale securities are reported as a net amount in accumulated other comprehensive gain or loss in stockholders’ equity until realized. Gains and losses on the sale of available-for-sale securities are determined using the specific identification method. The Company’s short term investments consist of corporate bonds and government agency bonds.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided over the estimated useful lives of the related assets, ranging from three to seven years, using the straight-line method. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately $369,000, $339,000 and $281,500 for years ended December 31, 2014, 2013 and 2012, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model.
Deposits, Policy [Polict Text Block]	Deposits Deposits include real property security deposits and other deposits which are contractually required and of a long-term nature.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Goodwill and In-Process Research and Development During 2014, the Company acquired certain assets of EGEN, Inc. As more fully described in Note 5, the acquisition was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. Under the acquisition method of accounting, the total purchase price is allocated to net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. Patent Licenses The Company has purchased several licenses for rights to patented technologies. Patent license costs of $63,125 have been capitalized and are amortized on a straight-line basis over the estimated life of the related patent. As of December 31, 2014, the total accumulated amortization expense is $41,500. The weighted-average amortization period for these assets is 10 years.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income and its components in the Company’s consolidated financial statements. The objective of ASC 220 is to report a measure (comprehensive income (loss)) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share Basic and diluted net income/(loss) per common share was computed by dividing net income/(loss) for the year by the weighted average number of shares of Common Stock outstanding, both basic and diluted, during each period. The impact of Common Stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. For the years ended December 31, 2014, 2013 and 2012, outstanding equity awards of 1,751,773, 863,462 and 729,825 shares, respectively, and warrants outstanding to purchase 5,069,815, 3,170,520 and 1,747,478 shares, respectively, were considered anti-dilutive and therefore were not included in the calculation of diluted shares.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category. The Company remains subject to examination for income tax returns for the years ending after 2010.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Compensation costs for all stock-based awards is measured at fair value on the date of the grant and recognized over the service period for awards expected to vest. Such value is recognized as expense over the service period. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the current estimates, such amounts will be recorded as cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by FASB and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations. In May 2014, the FASB issued Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Topic 606). This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. It will be effective for our first quarter of 2017 and early adoption is not permitted.

Note 3 - Short-term Investments Available for Sale (Tables)

12 Months Ended

Dec. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

	December 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Certificate of deposit	$	5,000,000	$	4,996,568	$	3,840,000	$	3,835,083
Bonds- corporate issuances		19,189,438		19,176,838		33,360,576		33,321,298
Total short-term investments	$	24,189,438	$	24,173,406	$	37,200,576	$	37,156,381

	December 31, 2014				December 31, 2013
	Cost		Fair Value		Cost		Fair Value

Short-term investment maturities
Within 3 months	$	16,881,490	$	16,872,158	$	7,799,032	$	7,797,689
Between 3-12 months		7,307,948		7,301,248		29,401,544		29,358,692
Total	$	24,189,438	$	24,173,406	$	37,200,576	$	37,156,381

Investment Income [Table Text Block]

	2014			2013			2012

Interest and dividends accrued and paid	$	1,015,182		$	748,947		$	712,947
Accretion of investment premium		(913,261	)		(669,344	)		(652,960	)
Losses on investment maturity and sales, net		(24,727	)		(92,346	)		(7,580	)
	$	77,194		$	(12,744	)	$	52,322

Schedule of Unrealized Loss on Investments [Table Text Block]

	December 31, 2014					December 31, 2013
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	–		–			$	6,650,095	$	1,907
Short-term investments with unrealized losses		24,173,406		(16,032	)		30,506,286		(46,073	)
Total	$	24,173,406	$	(16,032	)	$	37,156,381	$	(44,166	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Note 4 - Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets /Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of December 31, 2014
Short-term investments available for sale	$	24,173,406	$	24,173,406		─	─

Non-recurring items as of December 31, 2014
In-process research and development (Note 5)	$	25,801,728	─		─		$	25,801,728

Goodwill (Note 5)	$	1,976,101	─		─		$	1,976,101

Recurring items as of December 31, 2013
Short-term investments available for sale	$	37,156,381	$	37,156,381	─		─

Liabilities:
Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)	$	275,008	─		─		$	275,008

Earn-out milestone liability (Note 12)	$	13,663,710	─		─		$	13,663,710

As of December 31, 2013
Common stock warrant liability (Note 13)	$	3,026	─		─		$	3,026

Note 5 - Acquisition of EGEN, Inc. (Tables)

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Consideration Paid at Closing
Cash, net of cash acquired	$	2,821,000
Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)		9,438,000

Future Consideration
Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)		1,441,000
Earn-Out Payments (at fair value*)		13,878,000

Total fair value of consideration	$	27,578,000

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Property and equipment, net		35,000
In-process research and development		25,802,000
Goodwill		1,976,000
Total assets:		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

Business Acquisition, Pro Forma Information [Table Text Block]

	Year ended December 31,
	2014			2013
Revenues	$	500,000		$	627,628
Loss from operations		(24,898,725	)		(18,247,339	)
Net loss applicable to common shareholders		(25,662,572	)		(15,952,832	)

Note 6 - Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

	December 31, 2014			December 31, 2013
Machinery and equipment (5-7 year life)	$	2,298,516		$	1,674,206
Furniture and fixtures (3-5 year life)		235,679			153,051
Leasehold improvements (5-7 year life)		269,819			269,819
		2,804,014			2,097,076
Less accumulated depreciation and amortization		(1,633,517	)		(1,264,190	)
Total	$	1,170,497		$	832,886

Note 7 - Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

	December 31, 2014		December 31, 2013
Amounts due to Contract Research Organizations and other contractual agreements	$	857,730	$	1,711,934
Accrued payroll and related benefits		961,440		900,434
Accrued professional fees		502,300		63,500
Accrued interest on notes payable		96,875	–
Other		38,020		31,785
Total	$	2,456,365	$	2,707,653

Note 8 - Notes Payable (Tables)

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

	For the year ending December 31,

2015	$	3,654,231
2016		4,091,595
2017		2,254,174
2018 and thereafter	–
Total	$	10,000,000

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2014			2013			2012

Federal statutory rate		34.0	%		34.0	%		34.0	%
State taxes, net of federal tax benefit		5.5			5.9			5.9
Recapture of alternative minimum tax	–			–			–
Valuation allowance		(39.5	)		(39.9	)		(39.9	)

Effective tax rate		–	%		–	%		–	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31,
In thousands	2014			2013

Net operating loss carry forwards	$	61,536		$	53,423
Compensation expense related to employee stock options		4,235			3,310
Subtotal		65,771			56,733
Valuation allowance		(65,771	)		(56,733	)
Total deferred tax asset	$	-		$	-

Summary of Operating Loss Carryforwards [Table Text Block]

Approximate Amount of Unused Operating Loss Carry Forwards (in $000s)		Expiration During Year Ended
$	5,003		2022
	2,292		2023
	15,655		2024
	8,174		2025
	7,367		2026
	10,716		2028
	14,300		2029
	18,045		2030
	21,386		2031
	20,558		2032
	10,319		2033
	21,896		2034
$	155,711

Note 10 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Prefered Stock [Member]

Note 10 - Stockholders' Equity (Tables) [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Risk-free interest rate	0.78	%
Expected volatility	102.23	%
Expected life (in years)	5.0
Expected forfeiture rate	0.0	%
Expected dividend yield	0.0	%

Common Stock Offering [Member]

Note 10 - Stockholders' Equity (Tables) [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	June 3, 2013				October 28, 2013

Risk-free interest rate	0.50	-	1.03	%	0.59	-	1.31	%
Expected volatility	102.9	-	110.9	%	105.1	-	111.8	%
Expected life (in years)	3.1	-	4.7	%	2.7	-	4.3	%
Expected forfeiture rate		0.0		%		0.0		%
Expected dividend yield		0.00		%		0.00		%

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended December 31,
	2014				2013				2012
Risk-free interest rate	2.31	to	2.75	%	0.85	to	1.19	%	1.09	to	2.97	%
Expected volatility	94.3	-	100.7	%	83.4	-	97.9	%	80.8	-	82.3	%
Expected life (in years)		10			5.25	to	6.00		5.00	to	6.25
Expected forfeiture rate		10		%	5.0	to	7.5	%		7.5		%
Expected dividend yield		0.0		%		0.0		%		0.0		%

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Shares of common stock associated with the Waived Warrants		Expiration Date of Waived Warrants	Strike Price		Per Share Fair Value on June 3, 2013		Per Share Fair Value on October 28, 2013

	1,323,496	2/26/2018	$	5.31	$	6.60	$	3.86
	31,243	7/25/2016	$	18.99	$	4.41	$	2.10
	12,628	7/6/2016	$	14.09	$	4.81	$	2.40
	31,448	11/25/2017	$	12.47	$	5.56	$	3.16

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Note 11 - Stock Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Shar-based Compensation, Stock Options and Restricted Stock Awards, Activity [Table Text Block]

Stock Options	Number Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2012		691,809		$	16.88
Granted		145,611			10.08
Exercised		(47,575	)		14.67
Canceled or expired		(64,316	)		29.43
Outstanding at December 31, 2012		725,529		$	14.63
Granted		187,777			4.39
Exercised		(12,429	)		14.67
Canceled or expired		(38,972	)		16.79
Outstanding at December 31, 2013		861,905		$	12.29
Granted		1,014,700			3.53
Exercised	–			–
Canceled or expired		(131,850	)		19.05
Outstanding at December 31, 2014		1,744,755			7.20		7.5	$	-

Exercisable at December 31, 2014		990,936		$	9.71		6.1	$	-

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

Restricted Stock	Number Outstanding			Weighted Average Exercise Price
Non-vested stock awards outstanding at January 1, 2012		12,193		$	14.22
Granted		2,942			16.47
Vested and issued		(9,135	)		15.17
Forfeited		(1,703	)		12.56
Non-vested stock awards outstanding at December 31, 2012		4,297		$	14.63
Granted		111			5.36
Vested and issued		(444	)		8.40
Forfeited		(1,855	)		15.69
Non-vested stock awards outstanding at December 31, 2013		2,109		$	14.13
Granted		26,250			3.46
Vested and issued		(21,341	)		4.77
Forfeited	–			–
Non-vested stock awards outstanding at December 31, 2014		7,018		$	3.32

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

			Options Outstanding						Options Exercisable
		Range of Exercise Prices	Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price

$ 2.00	-	$3.99		956,700		9.4	$	3.53		293,266		9.4	$	3.54	$
$ 4.00	-	$8.99		185,778		7.6	$	4.46		131,044		7.2	$	4.41
$ 9.00	-	$13.49		434,445		4.9	$	11.12		401,461		4.7	$	11.25
$ 13.50	-	$31.49		165,870		3.4	$	20.81		163,203		3.3	$	20.80
Above $31.50				1,962		0.5	$	38.07		1,962		0.5	$	38.09
				1,744,755						990,936

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended December 31,
	2014				2013				2012
Risk-free interest rate	2.31	to	2.75	%	0.85	to	1.19	%	1.09	to	2.97	%
Expected volatility	94.3	-	100.7	%	83.4	-	97.9	%	80.8	-	82.3	%
Expected life (in years)		10			5.25	to	6.00		5.00	to	6.25
Expected forfeiture rate		10		%	5.0	to	7.5	%		7.5		%
Expected dividend yield		0.0		%		0.0		%		0.0		%

Note 12 - Earn Out Milestone Liability (Tables)

12 Months Ended

Dec. 31, 2014

Earn Out Milestone Liability Disclosure [Abstract]

Schedule of Changes in Earn-Out Milestone Liabilites [Table Text Block]

Balance at January 1, 2014	–
Fair value of Earn-Out Payments at date of EGEN Purchase Agreement (Note 5)		13,878,204
Gain from the adjustment for the change in fair value included in net income		(213,494	)
Balance at December 31, 2014	$	13,663,710

Note 13 - Warrants (Tables)

12 Months Ended

Dec. 31, 2014

Warrants [Abstract]

Schedule of Warrant Activity [Table Text Block]

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at January 1, 2012		2,583,778		$	14,18
Warrants issued in connection with the Oxford & Horizon Credit Agreement as more fully described in Note 8		11,415			13.14
Warrants exercised for common stock in 2012		(847,715	)		12.11
Warrants outstanding at December 31, 2012		1,747,478		$	15.17

Warrants issued in connection with 2013 equity transactions		1,341,382			5.31
Warrants issued in connection with the Hercules Credit Agreement (November 2013 tranche) as more fully described in Note 8		97,493			3.59
Warrants exercised for common stock in 2013		(15,833	)		14.63
Warrants outstanding at December 31, 2013		3,170,520		$	10.65

Warrants issued in connection with the January 2014 equity transaction		1,801,802			4.10
Warrants issued in connection with the Hercules Credit Agreement (June 2014 tranche) as more fully described in Note 8		97,493			3.59
Warrants outstanding at December 31, 2014		5,069,815		$	8.18


Aggregate intrinsic value of outstanding warrants at December 31, 2014	–

Weighted average remaining contractual terms (years)		2.4

Schedule of Common Stock Warrant Liability Valuation Assumptions [Table Text Block]

	December 31,
	2014			2013			2012
Risk-free interest rate		0.04 - 1.66	%		0.13	%		0.73	%
Expected volatility		40.9- 98.35	%		64.74	%		92.02	%
Expected life (in years)		0.25 -3.9			1.25			1.13
Expected forfeiture rate		0.0	%		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%		0.00	%

Schedule of Common Stock Warranty Liability [Table Text Block]

Balance at January 1, 2012	$	166,398
Benefit from the adjustment for the change in fair value included in net loss for 2011		4,117,534	)
Balance at December 31, 2012		4,283,932
Fair value of warrants classified as liability (see Note 10)		9,110,302
Fair value of warrants classified as equity (see Note 10)		(5,300,572	)
Gain from the adjustment for the change in fair value included in net loss		(8,090,636	)
Ending balance, December 31, 2013	$	3,026
Fair value of warrants classified as liability (see Note 8)		476,261
Gain from the adjustment for the change in fair value included in net income		(204,279	)
	$	275,008

Note 17 - Contingent Liabilities and Commitments (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

For the year ending December 31:	Operating Leases
2015	$	570,078
2016		575,513
2017		378,042
2018		23,200
2019 and beyond		—
Total minimum lease payments	$	1,546,833

Note 19 - Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

(in thousands, except per share data)	Quarters Ended
	March 31			June 30			September 30			December 31
2014
Total revenue	$	125		$	125		$	125		$	125
Net loss		(5,423	)		(6,673	)		(6,942	)		(6,455	)
Basic and diluted net loss per share		(0.33	)		(0.38	)		(0.35	)		(0.32	)

2013
Total revenue	$	125		$	125		$	125		$	125
Net loss		(651	)		421			(4,072	)		(3,949	)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		(4,601	)	─			─			─
Basic and diluted net loss available to common shareholders per share		(0.48	)		0.03			(0.30	)		(0.29	)

Note 1 - Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 30, 2014	Oct. 28, 2013	Dec. 31, 2011
Minimum [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Depreciation (in Dollars)	$ 369,000	$ 339,000	$ 281,500
Finite-Lived Patents, Gross (in Dollars)	63,125
Finite-Lived Intangible Assets, Accumulated Amortization (in Dollars)	$ 41,500
Finite-Lived Intangible Asset, Useful Life	10 years
Shares, Outstanding	1,751,773	863,462	729,825		9
Class of Warrant or Right, Outstanding	5,069,815	3,170,520	1,747,478	3,100,000		2,583,778

Note 2 - Financial Condition (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Financial Condition [Abstract]
Retained Earnings (Accumulated Deficit)	$ (195,073,702)	$ (169,287,157)

Note 3 - Short-term Investments Available for Sale (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2009
Short Term Investments Available For Sale [Member]
Note 3 - Short-term Investments Available for Sale (Details) [Line Items]
Short-term Investments			$ 24,173,406	$ 37,156,381
Short-term Investments			24,173,406	37,156,381
Available-for-sale Securities, Equity Securities					$ 108,000
Available-for-sale Securities			$ 24,173,406	$ 37,156,381	$ 903,112
Available-for-sale Securities, Gross Unrealized Loss		$ 0
Proceeds from Sale of Available-for-sale Securities	$ 138,000
Available-for-sale Securities, Gross Realized Gains	30,000
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	$ (108,000)

Note 3 - Short-term Investments Available for Sale (Details) - Short-Term Investment by Bond Maturities - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2009
Certificate of Deposit [Member]
Short-term investments
Short-term investments	$ 5,000,000	$ 3,840,000
Short-term investments	4,996,568	3,835,083
Corporate Debt Securities [Member]
Short-term investments
Short-term investments	19,189,438	33,360,576
Short-term investments	19,176,838	33,321,298
Investment Maturing Within 3 Months [Member]
Short-term investment maturities
Short-term investments maturities	16,881,490	7,799,032
Short-term investments maturities	16,872,158	7,797,689
Investment Maturing Between 3 and 12 Months [Member]
Short-term investment maturities
Short-term investments maturities	7,307,948	29,401,544
Short-term investments maturities	7,301,248	29,358,692
Short-term investments	24,189,438	37,200,576
Short-term investments	24,173,406	37,156,381	$ 903,112
Short-term investments maturities	24,189,438	37,200,576
Short-term investments maturities	$ 24,173,406	$ 37,156,381

Note 3 - Short-term Investments Available for Sale (Details) - Investment Income - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Investment Income [Abstract]
Interest and dividends accrued and paid	$ 1,015,182	$ 748,947			$ 712,947
Accretion of investment premium	(913,261)	(669,344)			(652,960)
Losses on investment maturity and sales, net	(24,727)	(92,346)			(7,580)
	$ 77,194	$ (12,744)	$ 77,194	$ (12,744)	$ 52,322

Note 3 - Short-term Investments Available for Sale (Details) - Investment Securities Gross Unrealized Losses and Fair Value by Investment Category - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Corporate Debt Securities [Member]
Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains		$ 6,650,095
Short-term investments with unrealized gains		1,907
Short-term investments with unrealized losses	$ 24,173,406	30,506,286
Short-term investments with unrealized losses	(16,032)	(46,073)
Total	24,173,406	37,156,381
Total	$ (16,032)	$ (44,166)

Note 4 - Fair Value of Financial Instruments (Details)	12 Months Ended
Note 4 - Fair Value of Financial Instruments (Details)	Dec. 31, 2014 USD ($)
Fair Value Disclosures [Abstract]
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	$ 0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3	0
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0

Note 4 - Fair Value of Financial Instruments (Details) - Assets and Liabilities at Fair Value on a Recurring Basis - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2009
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	$ 24,173,406	$ 37,156,381
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Recurring items as of December 31, 2014
Common stock warrant liability	275,008	3,026
Earn-out milestone liability (Note 12)	13,663,710
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Nonrecurring [Member]
Non-recurring items as of December 31, 2014
In-process research and development (Note 5)	25,801,728
Goodwill (Note 5)	1,976,101
Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	24,173,406	37,156,381
Recurring items as of December 31, 2014
Common stock warrant liability	275,008	3,026
Earn-out milestone liability (Note 12)	13,663,710
Fair Value, Measurements, Nonrecurring [Member]
Non-recurring items as of December 31, 2014
In-process research and development (Note 5)	25,801,728
Goodwill (Note 5)	1,976,101
Short-term investments available for sale Bonds – corporate issuances	24,173,406	$ 37,156,381	$ 903,112
Goodwill (Note 5)	1,976,101
Recurring items as of December 31, 2014
Earn-out milestone liability (Note 12)	$ 13,663,710

Note 5 - Acquisition of EGEN, Inc. (Details) - USD ($)

1 Months Ended

6 Months Ended

12 Months Ended

Aug. 02, 2016

Dec. 31, 2014

Jun. 10, 2014

Jun. 20, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 09, 2014

Ovarian Cancer Study Milestone [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 12,000,000

Glioblastoma Multiforme Brain Cancer Study Milestone [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

12,000,000

TheraSilence Technology Milestone [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

6,000,000

Scenario, Forecast [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)

670,070

In Process Research and Development [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Finite-lived Intangible Assets Acquired

25,800,000

Hercules Credit Agreement [Member] | EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Payments to Acquire Businesses, Gross

$ 3,000,000

Loans Payable

$ 5,000,000

EGEN, Inc. [Member] | Maximum [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Consideration Transferred

$ 44,400,000

EGEN, Inc. [Member]

Note 5 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Consideration Transferred

27,600,000

27,578,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

30,400,000

$ 30,400,000

Payments to Acquire Businesses, Gross

$ 3,000,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)

2,712,188

670,070

Business Combination, Consideration Transferred, Liabilities Incurred

$ 13,700,000

$ 13,900,000

$ 13,878,000

^[1]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

13,700,000

Fair Value, Option, Changes in Fair Value, Gain (Loss)

231,949

Goodwill, Acquired During Period

2,000,000

Reporting Unit, Amount of Fair Value in Excess of Carrying Amount

$ 2,000,000

Business Combination, Acquisition Related Costs

1,385,263

Operating Expenses

$ 2,297,000

Business Combination, Consideration Transferred, Liabilities Incurred

13,878,204

Business Combination, Acquisition Related Costs

1,385,263

Operating Expenses

$ 25,215,194

$ 15,911,485

$ 22,142,717

[1]

The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2014, the Company fair valued these milestones at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of these milestones from June 30, 2014.

Note 5 - Acquisition of EGEN, Inc. (Details) - Fair Value of Consideration - USD ($)

1 Months Ended

12 Months Ended

Dec. 31, 2014

Jun. 20, 2014

Dec. 31, 2014

EGEN, Inc. [Member]

Consideration Paid at Closing

Cash, net of cash acquired

$ 2,821,000

Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)

9,438,000

Future Consideration

Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)

1,441,000

Earn-Out Payments (at fair value*)

$ 13,700,000

$ 13,900,000

13,878,000

^[1]

Total fair value of consideration

$ 27,600,000

27,578,000

Cash, net of cash acquired

2,820,649

Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)

10,850,977

Earn-Out Payments (at fair value*)

$ 13,878,204

[1]

The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2014, the Company fair valued these milestones at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of these milestones from June 30, 2014.

Note 5 - Acquisition of EGEN, Inc. (Details) - Fair Value of Consideration (Parentheticals) - EGEN, Inc. [Member] - $ / shares	1 Months Ended	12 Months Ended
	Jun. 20, 2014	Dec. 31, 2014
Business Acquisition, Contingent Consideration [Line Items]
Common Stock, shares issued		2,712,188
Common Stock, price per share (in Dollars per share)		$ 3.48
Common Stock, shares to be issued	2,712,188	670,070
Common Stock, discount		38.00%

Note 5 - Acquisition of EGEN, Inc. (Details) - Summary of Estimated Fair Values of Acquired Assets and Liabilities	Dec. 31, 2014 USD ($)
EGEN, Inc. [Member]
Note 5 - Acquisition of EGEN, Inc. (Details) - Summary of Estimated Fair Values of Acquired Assets and Liabilities [Line Items]
Property and equipment, net	$ 35,000
In-process research and development	25,802,000
Goodwill	1,976,000
Total assets:	27,813,000
Accounts payable and accrued liabilities	(235,000)
Net assets acquired	27,578,000
Goodwill	$ 1,976,101

Note 5 - Acquisition of EGEN, Inc. (Details) - Pro Forma Information - EGEN, Inc. [Member] - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 5 - Acquisition of EGEN, Inc. (Details) - Pro Forma Information [Line Items]
Revenues	$ 500,000	$ 627,628
Loss from operations	(24,898,725)	(18,247,339)
Net loss applicable to common shareholders	$ (25,662,572)	$ (15,952,832)

Note 6 - Property, Plant and Equipment (Details) - Property, Plant, and Equipment Useful Life - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 2,298,516	$ 1,674,206
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	235,679	153,051
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	269,819	269,819
Property, plant, and equipment	2,804,014	2,097,076
Less accumulated depreciation and amortization	(1,633,517)	(1,264,190)
Total	$ 1,170,497	$ 832,886

Note 6 - Property, Plant and Equipment (Details) - Property, Plant, and Equipment Useful Life (Parentheticals)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years	5 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years	7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years	3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years	5 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years	5 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years	7 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

Note 7 - Other Accrued Liabilities (Details) - Accrued Liabilities - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Amounts due to Contract Research Organizations and other contractual agreements	$ 857,730	$ 1,711,934
Accrued payroll and related benefits	961,440	900,434
Accrued professional fees	502,300	63,500
Accrued interest on notes payable	96,875
Other	38,020	31,785
Total	$ 2,456,365	$ 2,707,653

Note 8 - Notes Payable (Details)		1 Months Ended					3 Months Ended		6 Months Ended	12 Months Ended			28 Months Ended
Note 8 - Notes Payable (Details)	Jun. 10, 2014 USD ($) $ / shares shares	Jun. 20, 2014 USD ($)	Nov. 30, 2013 USD ($)	Nov. 25, 2013 $ / shares shares	Jun. 30, 2012 USD ($)	Nov. 30, 2011 USD ($)	Jun. 30, 2014 USD ($) shares	Mar. 31, 2013 USD ($)	Jun. 10, 2014 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 $ / shares	Feb. 28, 2014 USD ($)	Jun. 09, 2014 USD ($) shares	Dec. 31, 2011 $ / shares
Lab Equipment [Member] \| November 2011 Capital Lease [Member]
Note 8 - Notes Payable (Details) [Line Items]
Capital Leased Assets, Gross						$ 144,448
Hercules Warrant [Member] \| First 50 Percent [Member] \| Hercules Credit Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) \| shares				97,493
Hercules Warrant [Member] \| First 50 Percent [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount							$ 260,928
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) \| shares							97,493
Hercules Warrant [Member] \| Second 50 Percent [Member] \| Hercules Credit Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) \| shares	97,493								97,493
Hercules Warrant [Member] \| Second 50 Percent [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount														$ 215,333
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) \| shares														97,493
Hercules Warrant [Member] \| Hercules Credit Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares				$ 3.59
Fair Value Assumptions, Expected Volatility Rate				102.00%
Fair Value Assumptions, Risk Free Interest Rate				1.37%
Fair Value Assumptions, Expected Term				5 years
Share Price (in Dollars per share) \| $ / shares				$ 3.55
Hercules Warrant [Member]
Note 8 - Notes Payable (Details) [Line Items]
Deferred Finance Costs, Net											$ 521,763
Fair Value Assumptions, Expected Volatility Rate	104.00%
Fair Value Assumptions, Risk Free Interest Rate	1.69%
Fair Value Assumptions, Expected Term	4 years 6 months
Share Price (in Dollars per share) \| $ / shares	$ 3.07								$ 3.07
Increase (Decrease) in Other Operating Assets							$ (521,763)
Adjustments to Additional Paid in Capital, Other							$ (521,763)
Number of Warrants Issued (in Shares) \| shares										97,493	97,493
Oxford & Horizon Warrants [Member]
Note 8 - Notes Payable (Details) [Line Items]
Deferred Finance Costs, Net										$ 73,654
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares										$ 13.14
Fair Value Assumptions, Expected Volatility Rate										74.30%
Fair Value Assumptions, Risk Free Interest Rate										1.10%
Fair Value Assumptions, Expected Term										3 years 6 months
Share Price (in Dollars per share) \| $ / shares										$ 12.60
Note Stock Conversion Rate										3.00%
Number of Warrants Issued (in Shares) \| shares										11,415
Warrants Issued Expiration Period										7 years
Hercules Credit Agreement [Member] \| EGEN, Inc. [Member]
Note 8 - Notes Payable (Details) [Line Items]
Payments to Acquire Businesses, Gross	$ 3,000,000
Hercules Credit Agreement [Member] \| Hercules [Member]
Note 8 - Notes Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 20,000,000
Proceeds from Lines of Credit	$ 5,000,000		5,000,000						$ 10,000,000
Debt Instrument, Basis Spread on Variable Rate				11.25%
Deferred Finance Costs, Net			122,378
Debt Instrument, Unamortized Discount			230,000
Line of Credit Facility, Original Loan Fee, Percent										3.50%
Deferred Finance Costs, Gross										$ 350,000
Hercules Credit Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Interest Expense, Debt										892,188
Amortization of Financing Costs										433,839
Oxford and Horizon Credit Agreement [Member] \| Oxford [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Percentage Funded by Certain Lender					50.00%
Oxford and Horizon Credit Agreement [Member] \| Horizon [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Percentage Funded by Certain Lender					50.00%
Oxford and Horizon Credit Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 10,000,000
Deferred Finance Costs, Net										217,715
Interest Expense, Debt								$ 146,874
Amortization of Financing Costs								$ 31,560
Loan Tranche Amount					$ 5,000,000
Repayments of Secured Debt										$ 4,100,000
Debt Instrument, Interest Rate, Stated Percentage								11.75%
EGEN, Inc. [Member]
Note 8 - Notes Payable (Details) [Line Items]
Payments to Acquire Businesses, Gross		$ 3,000,000
Share Price (in Dollars per share) \| $ / shares										$ 3.48
November 2011 Capital Lease [Member] \| November 2011 Capital Lease [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Periodic Payment													$ 5,651
November 2011 Capital Lease [Member]
Note 8 - Notes Payable (Details) [Line Items]
Capital Leases of Lessee, Number of Monthly Payments						30
Repayments of Long-term Capital Lease Obligations										$ 11,303
Oxford and Horizon [Member]
Note 8 - Notes Payable (Details) [Line Items]
Repayments of Lines of Credit			$ 4,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares										$ 8.18	$ 10.65	$ 15.17			$ 1,418
Fair Value Assumptions, Expected Volatility Rate											64.74%	92.02%
Fair Value Assumptions, Risk Free Interest Rate											0.13%	0.73%
Fair Value Assumptions, Expected Term											1 year 3 months	1 year 47 days
Increase (Decrease) in Other Operating Assets										$ 213,949
Number of Warrants Issued (in Shares) \| shares										1,801,802	1,341,382

Note 8 - Notes Payable (Details) - Future Principal Payments Due on the Credit Agreement - Hercules Credit Agreement [Member]	Dec. 31, 2014 USD ($)
Note 8 - Notes Payable (Details) - Future Principal Payments Due on the Credit Agreement [Line Items]
2015	$ 3,654,231
2016	4,091,595
2017	2,254,174
2018 and thereafter	0
Total	$ 10,000,000

Note 9 - Income Taxes (Details) - USD ($) $ in Thousands			1 Months Ended
Note 9 - Income Taxes (Details) - USD ($) $ in Thousands	Jun. 03, 2013	Feb. 05, 2013	Jul. 25, 2011	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 34,000	$ 34,000	$ 90,000	$ 155,711	$ 156,000
Operating Loss Carry Forwards Limitation on Use	$ 1,500	$ 1,400	$ 4,900

Note 9 - Income Taxes (Details) - Reconciliation of the Company's Statutory Tax Rate to the Effective Rate	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of the Company's Statutory Tax Rate to the Effective Rate [Abstract]
Federal statutory rate	34.00%	34.00%	34.00%
State taxes, net of federal tax benefit	5.50%	5.90%	5.90%
Recapture of alternative minimum tax	0.00%	0.00%	0.00%
Valuation allowance	(39.50%)	(39.90%)	(39.90%)
Effective tax rate	0.00%	0.00%	0.00%

Note 9 - Income Taxes (Details) - Components of the Company's Deferred Tax Asset - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Components of the Company's Deferred Tax Asset [Abstract]
Net operating loss carry forwards	$ 61,536	$ 53,423
Compensation expense related to employee stock options	4,235	3,310
Subtotal	65,771	56,733
Valuation allowance	$ (65,771)	$ (56,733)

Note 9 - Income Taxes (Details) - Approximate Amount Of Unused Operating Loss Carry Forwards and Expiration Dates - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Jun. 03, 2013	Feb. 05, 2013	Jul. 25, 2011
Expires 2022 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	$ 5,003
Expires 2023 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	2,292
Expires 2024 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	15,655
Expires 2025 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	8,174
Expires 2026 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	7,367
Expires 2028 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	10,716
Expires 2029 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	14,300
Expires 2030 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	18,045
Expires 2031 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	21,386
Expires 2032 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	20,558
Expires 2033 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	10,319
Expires 2034 [Member]
Operating Loss Carryforwards [Line Items]
Amount of unused operating loss carry forwards	21,896
$	$ 155,711	$ 156,000	$ 34,000	$ 34,000	$ 90,000

Note 10 - Stockholders' Equity (Details) - USD ($)						1 Months Ended					9 Months Ended	12 Months Ended
Note 10 - Stockholders' Equity (Details) - USD ($)	Jan. 15, 2014	Jun. 03, 2013	May 30, 2013	Feb. 22, 2013	Feb. 02, 2013	Jun. 20, 2014	Oct. 28, 2013	Feb. 26, 2013	Feb. 25, 2013	Aug. 31, 2012	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 30, 2014	Oct. 30, 2013	Oct. 29, 2013	Feb. 21, 2013	Dec. 31, 2011	Dec. 31, 2010
Series A Convertible Preferred Stock (Member) \| February 2013 Preferred Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				15,000.00422
Convertible Preferred Stock, Shares Issued upon Conversion								2,682,764
Dividends Payable, Current (in Dollars)								$ 4,600,000
Conversion of Stock, Shares Converted											15,000.00422
Series A Warrant [Member] \| January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.25
Series B Warrant [Member] \| January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.25
Waived Warrants [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Outstanding												1,398,816
January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	3,603,604
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,801,802
Stock Issued During Period, Value, New Issues (in Dollars)	$ 15,000,000
Common Stock, Shares Per Unit	1
Share Price (in Dollars per share)	$ 4.1625
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 4.10
ATM Agreement [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues									1,195,927
Aggregate Offering Price (in Dollars)					$ 25,000,000
Proceeds from Issuance of Common Stock (in Dollars)									$ 6,800,000
Commission on Proceeds from ATM Shares, Percent												3.00%
Legal Fees (in Dollars)												$ 50,000
February 2013 Preferred Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,341,382
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																		$ 5.31
Proceeds from Issuance or Sale of Equity (in Dollars)								$ 15,000,000
Warrants Issued Expiration Period								5 years
Warrants and Rights Outstanding (in Dollars)								$ 5,400,000
Conversion of Stock, Shares Issued											2,682,764
May 2013 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			1,392,109
Stock Issued During Period, Value, New Issues (in Dollars)			$ 9,800,000
Prior to Reverse Stock Split [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Outstanding																	13,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number																	3,900,000
EGEN, Inc. [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share)												$ 3.48
Stock Issued During Period, Shares, Acquisitions												2,712,188
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						2,712,188						670,070
Shelf Registration Statement Amount (in Dollars)										$ 75,000,000
Proceed From Exercise Of Warrants And Options (in Dollars)													$ 400,000	$ 10,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period													30,893	904,144
Proceeds from Warrant Exercises (in Dollars)												$ 0	$ 261,944	$ 10,106,557
Proceeds from Stock Options Exercised (in Dollars)												$ 0	$ 184,047	$ 697,220
Common Stock, Par or Stated Value Per Share (in Dollars per share)												$ 0.01	$ 0.01
Stock Issued During Period, Value, New Issues (in Dollars)													$ 18,217,852
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)												$ 8.18	$ 10.65	$ 15.17					$ 1,418
Proceeds from Issuance of Common Stock (in Dollars)												$ 13,788,811	$ 15,622,955
Proceed From Securities Offering (in Dollars)												$ 18,000,000
Conversion of Stock, Shares Issued													15,833	847,715
Class of Warrant or Right, Outstanding												5,069,815	3,170,520	1,747,478	3,100,000				2,583,778
Common Stock, Shares Authorized												75,000,000	75,000,000
Reclassification From Equity to Liability (in Dollars)		$ 9,100,000					$ 5,300,000					$ 476,261	$ 9,110,302
Shares, Outstanding							9					1,751,773	863,462	729,825
Shares, Issued							9
Common Stock, Shares, Outstanding							2					19,984,203	13,604,975			13,604,975	61,226,873
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number												1,744,755	861,905	725,529		900,000				691,809

Note 10 - Stockholders' Equity (Details) - Assumptions Used in the Valuation of the Warrants Associated with Preferred Stock Offering	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 28, 2013	Jun. 03, 2013	Dec. 31, 2014
Assumptions Used in the Valuation of the Warrants Associated with Preferred Stock Offering [Abstract]
Risk-free interest rate			0.78%
Expected volatility			102.23%
Expected life (in years)			5 years
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 10 - Stockholders' Equity (Details) - Waived Warrants - Estimate of Fair Value Measurement [Member] - $ / shares	Oct. 28, 2013	Jun. 03, 2013
February 26, 2018 [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 3.86	$ 6.60
Per share fair value	3.86	6.60
July 25, 2016 [Member]
Class of Warrant or Right [Line Items]
Strike price	2.10	4.41
Per share fair value	2.10	4.41
July 6, 2016 [Member]
Class of Warrant or Right [Line Items]
Strike price	2.40	4.81
Per share fair value	2.40	4.81
November 25, 2017 [Member]
Class of Warrant or Right [Line Items]
Strike price	3.16	5.56
Per share fair value	$ 3.16	$ 5.56

Note 10 - Stockholders' Equity (Details) - Assumptions for Valuation of Waived Warrants Associated with Common Stock Offering	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 28, 2013	Jun. 03, 2013	Dec. 31, 2014
Waived Warrants [Member] \| Minimum [Member]
Note 10 - Stockholders' Equity (Details) - Assumptions for Valuation of Waived Warrants Associated with Common Stock Offering [Line Items]
Risk-free interest rate	0.59%	0.50%
Expected volatility	105.10%	102.90%
Expected life (in years)	2 years 255 days	3 years 36 days
Waived Warrants [Member] \| Maximum [Member]
Note 10 - Stockholders' Equity (Details) - Assumptions for Valuation of Waived Warrants Associated with Common Stock Offering [Line Items]
Risk-free interest rate	1.31%	1.03%
Expected volatility	111.80%	110.90%
Expected life (in years)	4 years 109 days	4 years 255 days
Risk-free interest rate			0.78%
Expected volatility			102.23%
Expected life (in years)			5 years
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 11 - Stock Based Compensation (Details) - USD ($)	12 Months Ended					132 Months Ended
Note 11 - Stock Based Compensation (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2014	Oct. 30, 2013	Dec. 31, 2004	Dec. 31, 2001
Employee Stock Option [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,674,270					3,674,270
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	1,751,773
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,922,497					1,922,497
Issued To Consultants For Services [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0	5,555	5,387
Minimum [Member] \| Stock Incentive Plan 2007 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Percentage Of Fair Market Value Of Shares	110.00%					110.00%
Minimum [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Maximum [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Chief Executive Officer [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					95,555
Stock Option Plan 2001 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									148,148
Stock Incentive Plan 2004 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								148,148
Stock Incentive Plan 2007 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,444,444		944,444	444,444	222,222	3,444,444
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,500,000		500,000	222,222
Percentage Of Fair Market Value Of Shares	100.00%					100.00%
Percentage Of Outstanding Stock Determining Factor For Incentive Stock Price	10.00%					10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,040,950	187,888	148,553
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	131,850	41,379	66,019
Allocated Share-based Compensation Expense (in Dollars)	$ 2,600,000	$ 1,200,000	$ 1,100,000
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount (in Dollars)	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 1,300,000					$ 1,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$ 3.18	$ 3.40	$ 7.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	21,341	12,873	56,710
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	131,850	38,972	64,316
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		12,429	47,575
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,744,755	861,905	725,529	691,809		1,744,755	900,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		30,893	904,144
Allocated Share-based Compensation Expense (in Dollars)	$ 2,513,042	$ 1,235,437	$ 1,143,764
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	26,250	111	2,942

Note 11 - Stock Based Compensation (Details) - Stock Option and Restricted Stock Awards - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option and Restricted Stock Awards [Abstract]
Outstanding	861,905	725,529
Outstanding	$ 12.29	$ 14.63
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 6 months
Exercisable at December 31, 2014	990,936
Exercisable at December 31, 2014	$ 9.71
Exercisable at December 31, 2014	6 years 36 days
Granted	1,014,700	187,777	145,611
Granted	$ 3.53	$ 4.39	$ 10.08
Exercised		(12,429)	(47,575)
Exercised		$ 14.67	$ 14.67
Cancelled or expired	(131,850)	(38,972)	(64,316)
Cancelled or expired	$ 19.05	$ 16.79	$ 29.43
Outstanding	1,744,755	861,905	725,529
Outstanding	$ 7.20	$ 12.29	$ 14.63
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 6 months

Note 11 - Stock Based Compensation (Details) - Summary of the Status of the Company's Non-Vested Restricted Stock Awards - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of the Status of the Company's Non-Vested Restricted Stock Awards [Abstract]
Non-vested stock awards outstanding	2,109	4,297	12,193
Non-vested stock awards outstanding	$ 14.13	$ 14.63	$ 14.22
Granted	26,250	111	2,942
Granted	$ 3.46	$ 5.36	$ 16.47
Vested and issued	(21,341)	(444)	(9,135)
Vested and issued	$ 4.77	$ 8.40	$ 15.17
Forfeited		(1,855)	(1,703)
Forfeited		$ 15.69	$ 12.56
Non-vested stock awards outstanding	7,018	2,109	4,297
Non-vested stock awards outstanding	$ 3.32	$ 14.13	$ 14.63

Note 11 - Stock Based Compensation (Details) - Summary of Stock Option Awards And Changes - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Oct. 30, 2013	Dec. 31, 2012	Dec. 31, 2010
Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range of exercise prices	$ 2.00
Upper range of exercise prices	$ 3.99
Number of options outstanding (in Shares)	956,700
Weighted average remaining contractual term	9 years 146 days
Weighted average exercise price	$ 3.53
Number of options exercisable (in Shares)	293,266
Weighted average remaining contractual term	9 years 146 days
Weighted average exercise price	$ 3.54
Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range of exercise prices	4.00
Upper range of exercise prices	$ 8.99
Number of options outstanding (in Shares)	185,778
Weighted average remaining contractual term	7 years 219 days
Weighted average exercise price	$ 4.46
Number of options exercisable (in Shares)	131,044
Weighted average remaining contractual term	7 years 73 days
Weighted average exercise price	$ 4.41
Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range of exercise prices	9.00
Upper range of exercise prices	$ 13.49
Number of options outstanding (in Shares)	434,445
Weighted average remaining contractual term	4 years 328 days
Weighted average exercise price	$ 11.12
Number of options exercisable (in Shares)	401,461
Weighted average remaining contractual term	4 years 255 days
Weighted average exercise price	$ 11.25
Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range of exercise prices	13.50
Upper range of exercise prices	$ 31.49
Number of options outstanding (in Shares)	165,870
Weighted average remaining contractual term	3 years 146 days
Weighted average exercise price	$ 20.81
Number of options exercisable (in Shares)	163,203
Weighted average remaining contractual term	3 years 109 days
Weighted average exercise price	$ 20.80
Range 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in Shares)	1,962
Weighted average remaining contractual term	6 months
Weighted average exercise price	$ 38.07
Number of options exercisable (in Shares)	1,962
Weighted average remaining contractual term	6 months
Weighted average exercise price	$ 38.09
Number of options outstanding (in Shares)	1,744,755	861,905	900,000	725,529	691,809
Weighted average remaining contractual term	7 years 6 months
Weighted average exercise price	$ 7.20	$ 12.29		$ 14.63	$ 16.88
Number of options exercisable (in Shares)	990,936
Weighted average remaining contractual term	6 years 36 days

Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 28, 2013	Jun. 03, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member] \| Minimum [Member]
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Risk-free interest rate			2.31%	0.85%	1.09%
Expected volatility			94.30%	83.40%	80.80%
Expected life (in years)				5 years 3 months	5 years
Expected forfeiture rate				5.00%
Employee Stock Option [Member] \| Maximum [Member]
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Risk-free interest rate			2.75%	1.19%	2.97%
Expected volatility			100.70%	97.90%	82.30%
Expected life (in years)				6 years	6 years 3 months
Expected forfeiture rate				7.50%
Employee Stock Option [Member]
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Risk-free interest rate
Expected life (in years)			10 years
Expected forfeiture rate			10.00%		7.50%
Expected dividend yield			0.00%	0.00%	0.00%
Risk-free interest rate			0.78%
Expected volatility			102.23%
Expected life (in years)			5 years
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 12 - Earn Out Milestone Liability (Details) - USD ($)

1 Months Ended

12 Months Ended

Dec. 31, 2014

Jun. 20, 2014

Dec. 31, 2014

EGEN, Inc. [Member] | Minimum [Member]

Note 12 - Earn Out Milestone Liability (Details) [Line Items]

Risk-Adjusted Assessment of Each Milestone

10.00%

Estimated Time to Achieve the Milestone

1 year 73 days

1 year 6 months

EGEN, Inc. [Member] | Maximum [Member]

Note 12 - Earn Out Milestone Liability (Details) [Line Items]

Risk-Adjusted Assessment of Each Milestone

67.00%

Estimated Time to Achieve the Milestone

6 years 6 months

7 years

EGEN, Inc. [Member]

Note 12 - Earn Out Milestone Liability (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 30,400,000

Business Combination, Consideration Transferred, Liabilities Incurred

13,700,000

$ 13,900,000

13,878,000

^[1]

Gain (Loss) From Change in Fair Value of Earn-Out Milestone Liability

$ 231,949

Business Combination, Consideration Transferred, Liabilities Incurred

13,878,204

Gain (Loss) From Change in Fair Value of Earn-Out Milestone Liability

$ 213,494

[1]

The total aggregate purchase price for the Egen Acquisition included potential future Earn-Out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-Out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statement. As of December 31, 2014, the Company fair valued these milestones at $13.7 million and recognized a gain of $231,949 as a result of the change in the fair value of these milestones from June 30, 2014.

Note 12 - Earn Out Milestone Liability (Details) - Summary of the Changes in the Earn-Out Milestone Liability	12 Months Ended
	Dec. 31, 2014 USD ($)
Summary of the Changes in the Earn-Out Milestone Liability [Abstract]
Balance	$ 0
Fair value of Earn-Out Payments at date of EGEN Purchase Agreement (Note 5)	13,878,204
Gain from the adjustment for the change in fair value included in net income	(213,494)
Balance	$ 13,663,710

Note 13 - Warrants (Details) - USD ($)		1 Months Ended		12 Months Ended
Note 13 - Warrants (Details) - USD ($)	Jun. 03, 2013	Oct. 28, 2013	Sep. 30, 2009	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013	May 30, 2013	Jun. 30, 2012	Dec. 31, 2011
September 2009 Warrants [Member] \| Maximum [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercisable Term			66 months
September 2009 Warrants [Member] \| Minimum [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercisable Term			6 months
September 2009 Warrants [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			224,239
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 23.58
Waived Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Waived (in Shares)								1,398,816
September 2009 Registered Direct Offering [Member]
Note 13 - Warrants (Details) [Line Items]
Proceeds from Issuance or Sale of Equity			$ 7,100,000
Proceeds from Issuance or Sale of Equity, Net			$ 6,300,000
Common Stock and Warrants Issued, Shares (in Shares)			484,478
Waived Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
undefined		$ 5,300,000
Warrant Liability [Member]
Note 13 - Warrants (Details) [Line Items]
undefined				$ 204,279	$ 8,100,000	$ (4,100,000)
Hercules Credit Agreement [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							194,986
Oxford and Horizon Credit Agreement [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)									11,415
Number of Warrants Issued (in Shares)				1,801,802	1,341,382
Proceeds from Warrant Exercises				$ 0	$ 261,944	$ 10,106,557
Conversion of Stock, Shares Issued (in Shares)					15,833	847,715
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 8.18	$ 10.65	$ 15.17				$ 1,418
Reclassification From Equity to Liability	$ 9,100,000	$ 5,300,000		$ 476,261	$ 9,110,302
undefined					5,300,572
Common Stock Warrant Liability				$ 275,008	$ 3,026	$ 4,283,932				$ 166,398

Note 13 - Warrants (Details) - Summary of Warrant Activity - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Oxford & Horizon Warrant [Member]
Note 13 - Warrants (Details) - Summary of Warrant Activity [Line Items]
Warrant Issued			11,415
Warrant Issued			$ 13.14
Hercules Warrant [Member]
Note 13 - Warrants (Details) - Summary of Warrant Activity [Line Items]
Warrant Issued	97,493	97,493
Warrant Issued	$ 3.59	$ 3.59
Warrants outstanding	3,170,520	1,747,478	2,583,778
Warrants outstanding	$ 10.65	$ 15.17	$ 1,418
Weighted average remaining contractual terms (years)	2 years 146 days
Warrant Issued	1,801,802	1,341,382
Warrant Issued	$ 4.10	$ 5.31
Warrants exercised for common stock		(15,833)	(847,715)
Warrants exercised for common stock		$ 14.63	$ 12.11
Warrants outstanding	5,069,815	3,170,520	1,747,478
Warrants outstanding	$ 8.18	$ 10.65	$ 15.17

Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Minimum [Member]
Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions [Line Items]
Risk-free interest rate	0.04%
Expected volatility	40.90%
Expected life (in years)	3 months
Maximum [Member]
Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions [Line Items]
Risk-free interest rate	1.66%
Expected volatility	98.35%
Expected life (in years)	3 years 328 days
Risk-free interest rate		0.13%	0.73%
Expected volatility		64.74%	92.02%
Expected life (in years)		1 year 3 months	1 year 47 days
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 13 - Warrants (Details) - Common Stock Warrant Liability - USD ($)		1 Months Ended	12 Months Ended
	Jun. 03, 2013	Oct. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common Stock Warrant Liability [Abstract]
Common Stock Warrant Liability			$ 3,026	$ 4,283,932	$ 166,398
Fair value of warrants classified as liability	$ 9,100,000	$ 5,300,000	476,261	9,110,302
Gain from the adjustment for the change in fair value included in net income			(204,279)	(8,090,636)	4,117,534
Fair value of warrants classified as equity (see Note 10)				(5,300,572)
Gain from the adjustment for the change in fair value included in net loss				(8,090,636)
Common Stock Warrant Liability			$ 275,008	$ 3,026	$ 4,283,932

Note 14 - Celsion Employee Benefit Plans (Details)	12 Months Ended			123 Months Ended
Note 14 - Celsion Employee Benefit Plans (Details)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2018
Disclosure Text Block Supplement [Abstract]
Minimum Age For Employee Benefit Plan	21
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent				3.00%
Defined Benefit Plan, Contributions by Employer	$ 56,875	$ 57,239	$ 60,360

Note 15 - Licenses of Intellectual Property and Patents (Details)	12 Months Ended	182 Months Ended
	Dec. 31, 2014 USD ($) shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($) shares	Jan. 31, 2003 USD ($) shares
Disclosure Text Block [Abstract]
Number Of Days Before Issuance Factoring Into Average Closing Price		20 days
Amount Of Time After Effective Date Of License Agreement For Registration Rights To Take Place		1 year
Common Stock, Shares, Issued \| shares	20,097,603	20,097,603	13,737,970	253,691
Common Stock, Value, Issued \| $	$ 200,976	$ 200,976	$ 137,380	$ 2,200,000
Number Of Trademark Protection Application Pending For Thermo Dox	14

Note 16 - Technology Development and Licensing Agreements (Details) - USD ($)		3 Months Ended
	Jan. 18, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
Hisun [Member]
Note 16 - Technology Development and Licensing Agreements (Details) [Line Items]
Contractual Obligation			$ 209,000
Proceeds from License Fees Received	$ 5,000,000
Contractual Obligation			$ 857,730	$ 1,711,934
Deferred Revenue					$ 5,000,000
Deferred Revenue Amortization Period		10 years

Note 17 - Contingent Liabilities and Commitments (Details)	1 Months Ended					12 Months Ended
	Jun. 30, 2014 USD ($) ft²	Apr. 30, 2014 USD ($)	Apr. 30, 2013 USD ($)	Apr. 30, 2012 USD ($)	Jul. 31, 2011 ft²	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Standby Letters of Credit [Member] \| Lawrenceville, New Jersey [Member]
Note 17 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation				$ 250,000
Standby Letters of Credit [Member]
Note 17 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation Reduction Nineteen Months from Initial Term				50,000
Contractual Obligation Reduction Thirty-One Months from Initial Term				50,000
Contractual Obligation Reduction Forty-Three Months from Initial Term				50,000
Contractual Obligation Reduction				50,000
Contractual Obligation Remaining				100,000
Lawrenceville, New Jersey [Member]
Note 17 - Contingent Liabilities and Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²					10,870
Number of Months in Which Free Rent is Provided					6 months
Lessee Leasing Arrangements, Operating Leases, Term of Contract					66 months
Payments for Rent				23,000
Escrow Deposit Related To Operating Lease				$ 250,000
Premises Located in Huntsville, Alabama [Member]
Note 17 - Contingent Liabilities and Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²	11,500
Lessee Leasing Arrangements, Operating Leases, Term of Contract	43 months
Operating Leases, Monthly Rent Payment	$ 23,200
Payments for Rent						$ 425,443	$ 280,808	$ 184,790
Contractual Obligation						$ 857,730	$ 1,711,934
Reduction of Escrow Deposit		$ 50,000	$ 50,000

Note 17 - Contingent Liabilities and Commitments (Details) - Summary of the Future Minimum Payments Required Under Leases	Dec. 31, 2014 USD ($)
Summary of the Future Minimum Payments Required Under Leases [Abstract]
2015	$ 570,078
2016	575,513
2017	378,042
2018	23,200
Total minimum lease payments	$ 1,546,833

Note 19 - Selected Quarterly Financial Data (Unaudited) (Details) - Selected Quarterly Financial Data - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarter 1 [Member]
2014
Total revenue	$ 125,000	$ 125,000
Net loss	$ (5,423,000)	(651,000)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		$ (4,601,000)
Basic and diluted net loss (in Dollars per share)	$ (0.33)	$ (0.48)
Quarter 2 [Member]
2014
Total revenue	$ 125,000	$ 125,000
Net loss	$ (6,673,000)	$ 421,000
Basic and diluted net loss (in Dollars per share)	$ (0.38)	$ 0.03
Quarter 3 [Member]
2014
Total revenue	$ 125,000	$ 125,000
Net loss	$ (6,942,000)	$ (4,072,000)
Basic and diluted net loss (in Dollars per share)	$ (0.35)	$ (0.30)
Quarter 4 [Member]
2014
Total revenue	$ 125,000	$ 125,000
Net loss	$ (6,455,000)	$ (3,949,000)
Basic and diluted net loss (in Dollars per share)	$ (0.32)	$ (0.29)
Net loss	$ (25,494,273)	$ (8,251,358)	$ (26,568,382)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock		$ 4,601,410

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Label	Element	Value
July 252016 [Member]
Shares of common stock associated with waived warrants (in Shares)	us-gaap_ClassOfWarrantOrRightOutstanding	31,243
Strike price	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	$ 18.99
Expiration date of waived warrants	clsn_ExpirationDateOfWarrants	Jul. 25, 2016
July 62016 [Member]
Shares of common stock associated with waived warrants (in Shares)	us-gaap_ClassOfWarrantOrRightOutstanding	12,628
Strike price	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	$ 14.09
Expiration date of waived warrants	clsn_ExpirationDateOfWarrants	Jul. 06, 2016
February 262018 [Member]
Shares of common stock associated with waived warrants (in Shares)	us-gaap_ClassOfWarrantOrRightOutstanding	1,323,496
Strike price	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	$ 5.31
Expiration date of waived warrants	clsn_ExpirationDateOfWarrants	Feb. 26, 2018
November 252017 [Member]
Shares of common stock associated with waived warrants (in Shares)	us-gaap_ClassOfWarrantOrRightOutstanding	31,448
Strike price	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	$ 12.47
Expiration date of waived warrants	clsn_ExpirationDateOfWarrants	Nov. 25, 2017